Public Sample ID,Linkcode,Diagnosis,Abnormal Cognition,Motor Symptoms,Plate,Well Position,Original Tube Type,Aliquot Tube Type,Inaccurate Volume Provided (ul),Aliquot Batch,Aliquot Qty,Extra in OT,OT postion,Box Position,Box Label,Aliqs Position,Group,Age,isMale,Sex,Cutpoint,ptau181 (pg/ml),Ttau (pg/ml),AB42/AB40,AB42 (pg/ml),Abeta40,Y1 Consensus,Y2 Consensus,Y3 Consensus,Y4 Consensus,Notes,CSF availability,Apo E2 (nmol/L) (CLAVY),Apo E3 (nmol/L),Apo E4 (nmol/L) (LGAD),Total ApoE (average),ApoE Phenotype,SELLE (nmol/L),ApoE Genotype (Kathleen group),Comparision genotype/phenotype,Cohort,Month Collected,Year Collected,alpha syn
TPAD0200,181,HC,0,0,1B,E1,vial,2 ml Sarstedt low bind vial,500,2,7,no,B1,4_D1_4B,TPAD CSF Aliquots Batch2 Box8,B2-B8,1,66,1,Male,Cutpoint #1,103,690,0.11,2335,21148,HC,HC,HC,none,none,additional sample possibly available,0,170.1,0,170.1,E3_E3,150.5,E3_E3,TRUE,Cohort 1,March,2018,not completed
TPAD0201,203,HC,0,0,5,E6,0.5 ml clear tube,2 ml Sarstedt low bind vial,500,3,8,no,G4,4_D1_5B,TPAD CSF Aliquots Batch3 Box3,G5-H3,1,81,1,Male,Cutpoint #1,37.3,264.8,0.1,906.3,8653.9,none,none,none,none,none,additional sample possibly available,0,70.9,0,70.9,E3_E3,62.7,E3_E3,TRUE,Cohort 2,March,2019,not completed
TPAD0202,301,HC,0,0,2A,D7,vial,1.5 ml Eppendorf low bind tube,500,1,7,no,A1,4_D1_2B,TPAD CSF Aliquots Batch1 Box7,A2-A7,1,71,1,Male,Cutpoint #1,43.5,371.8,0.12,1560.3,12734.9,none,none,none,none,none,additional sample most likely available,0,84.1,0,84.1,E3_E3,79.1,E3_E3,TRUE,Cohort 2,January,2019,not completed
TPAD0203,475,HC,0,0,2B,H8,0.5 ml purple tube,2 ml Sarstedt low bind vial,500,4,8,no,D8,4_D2_2C,TPAD CSF Aliquots Batch4 Box4,D9-E7,1,75,1,Male,Cutpoint #1,28.4,170.8,0.12,979.3,8106.9,none,none,none,none,none,additional sample most likely available,0,64,0,64,E3_E3,60.1,E3_E3,TRUE,Cohort 2,March,2019,not completed
TPAD0204,479,HC,0,0,2B,G2,vial,2 ml Sarstedt low bind vial,500,3,8,no,H1,4_D1_5D,TPAD CSF Aliquots Batch3 Box5,H2-H9,1,75,0,Female,Cutpoint #1,47,302.8,0.07,484.3,6480.9,none,none,none,none,none,additional sample most likely available,0,47.2,0,47.2,E3_E3,41.3,E3_E3,TRUE,Cohort 2,June,2019,not completed
TPAD0205,481,HC,0,0,3B,E8,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,F1,4_D1_2A,TPAD CSF Aliquots Batch1 Box6,F2-F8,1,75,0,Female,Cutpoint #1,33.8,243.8,0.12,1056.3,9022.9,none,none,none,none,none,additional sample most likely available,0,64,0,64,E3_E3,60.5,na,FALSE,Cohort 2,January,2019,not completed
TPAD0206,489,HC,0,0,2A,D12,0.5 ml purple tube,2 ml Sarstedt low bind vial,500,2,8,no,D1,4_D1_3B,TPAD CSF Aliquots Batch2 Box3,D2-D9,1,73,1,Male,Cutpoint #1,38.8,256.8,0.12,1182.3,10163.9,none,none,none,none,none,additional sample most likely available,0,84.2,0,84.2,E3_E3,78.5,E3_E3,TRUE,Cohort 2,February,2019,not completed
TPAD0207,532,HC,0,0,2B,F12,vial,1.5 ml Eppendorf low bind tube,500,1,7,no,E1,4_D1_2A,TPAD CSF Aliquots Batch1 Box6,E2-E7,1,74,0,Female,Cutpoint #1,37.3,306.8,0.11,1041.3,9638.9,none,none,none,none,none,additional sample most likely available,0,29.3,32.1,61.4,E3_E4,58.5,E3_E4,TRUE,Cohort 2,March,2019,not completed
TPAD0208,534,HC,0,0,2A,C12,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,G1,4_D1_2A,TPAD CSF Aliquots Batch1 Box6,G2-G8,1,70,0,Female,Cutpoint #1,17.7,132.8,0.15,685.3,4572.9,none,none,none,none,none,additional sample most likely available,0,33.7,0,33.7,E3_E3,31.1,E3_E3,TRUE,Cohort 2,May,2019,not completed
TPAD0209,564,HC,0,0,3B,E12,vial,2 ml Sarstedt low bind vial,500,2,8,no,G7,4_D1_3C,TPAD CSF Aliquots Batch2 Box4,G8-H6,1,75,1,Male,Cutpoint #1,48.9,366.8,0.11,1393.3,13109.9,none,none,none,none,none,additional sample most likely available,43.1,56.3,0,99.4,E2_E3,89.5,E2_E3,TRUE,Cohort 2,July,2019,not completed
TPAD0210,587,MCI,1,0,2A,C3,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,A1,4_D1_2D,TPAD CSF Aliquots Batch1 Box9,A2-A8,2,78,1,Male,Cutpoint #1,152.7,844,0.06,918,16016,MCI,MCI,none,none,none,additional sample most likely available,0,84.7,97.7,182.4,E3_E4,177.7,E3_E4,TRUE,Cohort 1,July,2019,SSA negative
TPAD0211,592,HC,0,0,3B,F1,vial,1.5 ml Eppendorf low bind tube,500,1,7,no,A1,4_D1_2A,TPAD CSF Aliquots Batch1 Box6,A2-A7,1,81,1,Male,Cutpoint #1,35.9,259.8,0.09,790.3,8659.9,none,none,none,none,none,additional sample most likely available,0,40.2,46.3,86.5,E3_E4,79.6,E3_E4,TRUE,Cohort 2,May,2019,not completed
TPAD0212,611,HC,0,0,2B,E7,vial,2 ml Sarstedt low bind vial,500,4,9,no,A1,4_D2_3A,TPAD CSF Aliquots Batch4 Box7,A2-B1,1,71,0,Female,Cutpoint #1,30.5,225.8,0.12,811.3,7033.9,none,none,none,none,none,additional sample most likely available,0,61.3,0,61.3,E3_E3,61.7,E3_E3,TRUE,Cohort 2,November,2019,not completed
TPAD0213,613,HC,0,0,3A,C10,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,D1,4_D1_2A,TPAD CSF Aliquots Batch1 Box6,D2-D8,1,67,1,Male,Cutpoint #1,26.2,206.8,0.11,1131.3,9856.9,HC,HC,HC,HC,none,additional sample most likely available,0,50.2,0,50.2,E3_E3,49.6,E3_E3,TRUE,Cohort 1 and Cohort 2,November,2015,not completed
TPAD0214,619,HC,0,0,5,C5,1.5 ml clear tube,2 ml Sarstedt low bind vial,500,2,8,no,A1,4_D1_3C,TPAD CSF Aliquots Batch2 Box4,A2-A9,1,75,1,Male,Cutpoint #1,46,298,0.08,840,10433,HC,HC,HC,HC,none,no additional sample possible,0,56.8,69.1,125.9,E3_E4,114.2,E3_E4,TRUE,Cohort 1,October,2015,not completed
TPAD0215,629,HC,0,0,1A,A4,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,C1,4_D1_2A,TPAD CSF Aliquots Batch1 Box6,C2-C8,1,79,1,Male,Cutpoint #1,34.9,244.8,0.12,790.3,6728.9,HC,HC,HC,HC,none,additional sample most likely available,0,78.3,0,78.3,E3_E3,74.7,E3_E3,TRUE,Cohort 1 and Cohort 2,January,2016,not completed
TPAD0216,638,HC,0,0,2B,F4,vial,1.5 ml Eppendorf low bind tube,500,1,7,no,B1,4_D1_2A,TPAD CSF Aliquots Batch1 Box6,B2-B7,1,62,0,Female,Cutpoint #1,30.2,214.8,0.12,945.3,7933.9,HC,HC,HC,HC,none,additional sample most likely available,0,69.4,0,69.4,E3_E3,58.4,E3_E3,TRUE,Cohort 1 and Cohort 2,December,2015,not completed
TPAD0217,641,HC,0,0,1A,C5,vial,2 ml Sarstedt low bind vial,500,3,8,no,F1,4_D1_5D,TPAD CSF Aliquots Batch3 Box5,F2-F9,1,77,0,Female,Cutpoint #1,33.5,301.8,0.12,1126.3,9399.9,none,none,none,none,none,additional sample most likely available,0,98.1,0,98.1,E3_E3,89.8,E3_E3,TRUE,Cohort 2,October,2019,not completed
TPAD0218,674,HC,0,0,5,B7,vial,2 ml Sarstedt low bind vial,500,2,8,no,A1,4_D1_3D,TPAD CSF Aliquots Batch2 Box5,A2-A9,1,80,0,Female,Cutpoint #1,66.6,397.8,0.06,522.3,9035.9,none,none,none,none,none,additional sample most likely available,0,0,118.9,116.9,E4_E4,91.9,E4_E4,TRUE,Cohort 2,October,2019,not completed
TPAD0219,687,HC,0,0,3B,F2,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,G1,4_D1_1E,TPAD CSF Aliquots Batch1 Box5,G2-G8,1,76,0,Female,Cutpoint #1,38.5,289.8,0.13,1532.3,11787.9,HC,HC,HC,HC,none,additional sample most likely available,0,79.2,0,79.2,E3_E3,70.6,E3_E3,TRUE,Cohort 1 and Cohort 2,August,2016,not completed
TPAD0220,782,HC,0,0,3A,B7,vial,2 ml Sarstedt low bind vial,500,2,9,yes,G1,4_D1_4A,TPAD CSF Aliquots Batch2 Box7,G2-H1,1,78,1,Male,Cutpoint #1,44.1,309.8,0.12,1383.3,11248.9,none,none,none,none,none,most likely no additional sample,0,106.3,0,106.3,E3_E3,106.7,E3_E3,TRUE,Cohort 2,January,2017,not completed
TPAD0221,795,HC,0,0,3B,G3,vial,2 ml Sarstedt low bind vial,500,4,9,yes,F9,4_D2_3C,TPAD CSF Aliquots Batch4 Box9,G1-G9,1,73,0,Female,Cutpoint #1,31.2,250.8,0.12,1113.3,9008.9,none,none,none,none,none,most likely no additional sample,0,82.4,0,82.4,E3_E3,76.7,na,FALSE,Cohort 2,March,2017,not completed
TPAD0222,797,HC,0,0,2A,A7,vial,2 ml Sarstedt low bind vial,500,4,9,yes,H1,4_D2_3C,TPAD CSF Aliquots Batch4 Box9,H2-I1,1,84,1,Male,Cutpoint #1,42.9,359.8,0.13,1645.3,12809.9,none,none,none,none,none,most likely no additional sample,46,53.6,0,99.7,E2_E3,96.9,E2_E3,TRUE,Cohort 2,February,2017,not completed
TPAD0223,798,HC,0,0,1B,H2,vial,2 ml Sarstedt low bind vial,500,4,8,no,B1,4_D2_3D,TPAD CSF Aliquots Batch4 Box10,B2-B9,1,65,0,Female,Cutpoint #1,34.2,279.8,0.12,1184.3,9768.9,none,none,none,none,none,most likely no additional sample,0,94.5,0,94.5,E3_E3,85.1,E3_E3,TRUE,Cohort 2,March,2017,not completed
TPAD0224,814,HC,0,0,1A,C12,vial,2 ml Sarstedt low bind vial,500,2,9,yes,H2,4_D1_4A,TPAD CSF Aliquots Batch2 Box7,H3-I2,1,64,1,Male,Cutpoint #1,52.8,395.8,0.12,1883.3,15385.9,none,none,none,none,none,most likely no additional sample,46.7,55.8,0,102.4,E2_E3,100.3,E2_E3,TRUE,Cohort 2,March,2017,not completed
TPAD0225,826,HC,0,0,5,A11,vial,2 ml Sarstedt low bind vial,500,2,8,no,F1,4_D1_4A,TPAD CSF Aliquots Batch2 Box7,F2-F9,1,71,0,Female,Cutpoint #1,40.7,257.8,0.07,484.3,6934.9,none,none,none,none,none,most likely no additional sample,0,53.6,0,53.6,E3_E3,52.7,E3_E3,TRUE,Cohort 2,April,2017,not completed
TPAD0226,827,HC,0,0,1A,B8,vial,2 ml Sarstedt low bind vial,500,3,8,no,G1,4_D2_1A,TPAD CSF Aliquots Batch3 Box7,G2-G9,1,64,1,Male,Cutpoint #1,38.9,302.8,0.1,961.3,10024.9,none,none,none,none,none,most likely no additional sample,0,79.3,0,79.3,E3_E3,66.7,E3_E3,TRUE,Cohort 2,May,2017,not completed
TPAD0227,832,HC,0,0,5,D11,vial,2 ml Sarstedt low bind vial,500,3,8,no,H1,4_D2_1A,TPAD CSF Aliquots Batch3 Box7,H2-H9,1,74,0,Female,Cutpoint #1,36.2,282.8,0.11,957.3,8630.9,none,none,none,none,none,most likely no additional sample,0,32.4,39.3,71.7,E3_E4,72.3,E3_E4,TRUE,Cohort 2,May,2017,not completed
TPAD0228,834,HC,0,0,5,A6,vial,2 ml Sarstedt low bind vial,500,2,7,no,E1,4_D1_4A,TPAD CSF Aliquots Batch2 Box7,E2-E8,1,91,1,Male,Cutpoint #1,63.5,356.8,0.08,669.3,8534.9,none,none,none,none,none,most likely no additional sample,0,63.6,0,63.6,E3_E3,56.8,E3_E3,TRUE,Cohort 2,June,2017,not completed
TPAD0229,841,HC,0,0,3A,B3,1.5 ml clear tube,2 ml Sarstedt low bind vial,500,3,8,no,H3,4_D1_5C,TPAD CSF Aliquots Batch3 Box4,H4-I2,1,72,1,Male,Cutpoint #1,57.5,435,0.08,762,9417,none,none,none,none,none,most likely no additional sample,0,91.4,0,91.4,E3_E3,87.5,E3_E3,TRUE,Cohort 1,May,2017,not completed
TPAD0230,843,HC,0,0,5,B2,vial,2 ml Sarstedt low bind vial,500,4,9,no,H1,4_D2_3B,TPAD CSF Aliquots Batch4 Box8,H2-I1,1,65,0,Female,Cutpoint #1,35.6,311.8,0.12,1380.3,11447.9,none,none,none,none,none,most likely no additional sample,0,67.9,0,67.9,E3_E3,60.2,E3_E3,TRUE,Cohort 2,May,2017,not completed
TPAD0231,846,HC,0,0,1B,G4,vial,2 ml Sarstedt low bind vial,500,3,8,no,D1,4_D2_1B,TPAD CSF Aliquots Batch3 Box8,D2-D9,1,62,0,Female,Cutpoint #1,28.2,270,0.15,1682,11223,HC,HC,HC,HC,none,most likely no additional sample,0,60.8,0,60.8,E3_E3,64.7,E3_E3,TRUE,Cohort 1,May,2017,not completed
TPAD0232,849,HC,0,0,2A,D2,1.5 ml clear tube,2 ml Sarstedt low bind vial,500,3,8,no,A1,4_D1_5D,TPAD CSF Aliquots Batch3 Box5,A2-A9,1,64,1,Male,Cutpoint #1,23.2,190,0.14,996,7050,HC,HC,HC,HC,none,most likely no additional sample,0,99.2,0,99.2,E3_E3,91.2,E3_E3,TRUE,Cohort 1,May,2017,not completed
TPAD0233,851,HC,0,0,3B,F5,vial,2 ml Sarstedt low bind vial,500,2,8,no,C1,4_D1_4A,TPAD CSF Aliquots Batch2 Box7,C2-C9,1,77,1,Male,Cutpoint #1,25.4,180.8,0.12,807.3,6653.9,none,none,none,none,none,most likely no additional sample,0,56,0,56,E3_E3,54.3,E3_E3,TRUE,Cohort 2,June,2017,not completed
TPAD0234,852,HC,0,0,2B,G5,vial,2 ml Sarstedt low bind vial,500,2,8,no,C1,4_D1_4B,TPAD CSF Aliquots Batch2 Box8,C2-C9,1,71,0,Female,Cutpoint #1,34.4,243.8,0.11,957.3,8475.9,none,none,none,none,none,most likely no additional sample,39.1,42,0,81.1,E2_E3,78,na,FALSE,Cohort 2,June,2017,not completed
TPAD0235,858,HC,0,0,4,D9,vial,2 ml Sarstedt low bind vial,500,3,8,no,I1,4_D2_1A,TPAD CSF Aliquots Batch3 Box7,I2-I9,1,72,1,Male,Cutpoint #1,34.7,239.8,0.12,1002.3,8312.9,none,none,none,none,none,most likely no additional sample,0,102.8,0,102.8,E3_E3,99.6,E3_E3,TRUE,Cohort 2,June,2017,not completed
TPAD0236,859,HC,0,0,2A,D8,vial,2 ml Sarstedt low bind vial,500,3,8,no,C1,4_D2_1A,TPAD CSF Aliquots Batch3 Box7,C2-C9,1,70,0,Female,Cutpoint #1,38.4,284.8,0.13,1423.3,11253.9,none,none,none,none,none,additional sample possibly available,0,105.5,0,105.5,E3_E3,95.8,na,FALSE,Cohort 2,June,2017,not completed
TPAD0237,862,HC,0,0,5,A12,vial,2 ml Sarstedt low bind vial,500,2,8,no,A1,4_D1_4B,TPAD CSF Aliquots Batch2 Box8,A2-A9,1,79,0,Female,Cutpoint #1,56.9,395.8,0.07,671.3,9343.9,none,none,none,none,none,most likely no additional sample,0,82.6,0,82.6,E3_E3,73,E3_E3,TRUE,Cohort 2,July,2017,not completed
TPAD0238,866,HC,0,0,5,C12,vial,2 ml Sarstedt low bind vial,500,2,7,no,D1,4_D1_4A,TPAD CSF Aliquots Batch2 Box7,D2-D8,1,80,1,Male,Cutpoint #1,38.9,317.8,0.13,1336.3,10556.9,none,none,none,none,none,additional sample possibly available,0,72.4,0,72.4,E3_E3,69.1,E3_E3,TRUE,Cohort 2,July,2017,not completed
TPAD0239,867,HC,0,0,5,A7,vial,2 ml Sarstedt low bind vial,500,3,8,no,F1,4_D2_1A,TPAD CSF Aliquots Batch3 Box7,F2-F9,1,64,0,Female,Cutpoint #1,37.8,262.8,0.09,586.3,6788.9,none,none,none,none,none,most likely no additional sample,0,0.5,58.5,58.9,E4_E4,52,E4_E4,TRUE,Cohort 2,July,2017,not completed
TPAD0240,869,HC,0,0,4,B1,1.5 ml clear tube,2 ml Sarstedt low bind vial,500,4,7,no,D3,4_D2_2E,TPAD CSF Aliquots Batch4 Box6,D4-E1,1,67,1,Male,Cutpoint #1,39.1,244,0.14,1348,9890,HC,HC,HC,none,none,most likely no additional sample,0,127.6,0,127.6,E3_E3,117.9,E3_E3,TRUE,Cohort 1,July,2017,not completed
TPAD0241,870,PD-noMCI,0,1,1B,G2,vial,2 ml Sarstedt low bind vial,500,4,7,no,A1,4_D2_3C,TPAD CSF Aliquots Batch4 Box9,A2-A8,3,72,0,Female,Cutpoint #1,23.7,152,0.13,1089,8361,PD-noMCI,PD-noMCI,none,none,none,additional sample most likely available,0,100,0,100,E3_E3,91.1,E3_E3,TRUE,Cohort 1,April,2018,SSA positive
TPAD0242,871,HC,0,0,5,D8,vial,2 ml Sarstedt low bind vial,500,4,9,yes,C1,4_D2_3D,TPAD CSF Aliquots Batch4 Box10,C2-D1,1,77,0,Female,Cutpoint #1,46.5,340,0.14,1750,12542,HC,HC,HC,HC,none,most likely no additional sample,65.9,78.9,0,144.8,E2_E3,138.4,E2_E3,TRUE,Cohort 1,August,2017,not completed
TPAD0243,878,HC,0,0,4,A11,vial,2 ml Sarstedt low bind vial,500,2,7,no,B1,4_D1_4A,TPAD CSF Aliquots Batch2 Box7,B2-B8,1,63,0,Female,Cutpoint #1,36.9,238.8,0.1,1189.3,11572.9,none,none,none,none,none,additional sample possibly available,0,101.6,0,101.6,E3_E3,91.6,E3_E3,TRUE,Cohort 2,August,2017,not completed
TPAD0244,883,HC,0,0,1A,D3,1.5 ml clear tube,2 ml Sarstedt low bind vial,500,2,6,no,F9,4_D1_3C,TPAD CSF Aliquots Batch2 Box4,G1-G6,1,77,0,Female,Cutpoint #1,44,307.8,0.1,1293.3,13336.9,none,none,none,none,none,most likely no additional sample,0,94.4,0,94.4,E3_E3,89.8,E3_E3,TRUE,Cohort 2,August,2017,not completed
TPAD0245,885,HC,0,0,2A,D4,1.5 ml clear tube,2 ml Sarstedt low bind vial,500,2,8,no,B1,4_D1_3C,TPAD CSF Aliquots Batch2 Box4,B2-B9,1,72,1,Male,Cutpoint #1,37.9,264,0.13,1286,9886,HC,HC,HC,HC,none,most likely no additional sample,0,40.8,49.4,90.2,E3_E4,85.4,E3_E4,TRUE,Cohort 1,July,2017,not completed
TPAD0246,887,HC,0,0,5,D12,vial,2 ml Sarstedt low bind vial,500,2,8,no,I1,4_D1_3E,TPAD CSF Aliquots Batch2 Box6,I2-I9,1,70,1,Male,Cutpoint #1,55.5,389.8,0.08,812.3,9927.9,none,none,none,none,none,most likely no additional sample,0,35.6,41.7,77.3,E3_E4,75.3,na,FALSE,Cohort 2,September,2017,not completed
TPAD0247,888,HC,0,0,3B,E3,vial,2 ml Sarstedt low bind vial,500,2,8,no,A1,4_D1_4A,TPAD CSF Aliquots Batch2 Box7,A2-A9,1,67,0,Female,Cutpoint #1,42.1,297.8,0.09,1072.3,12165.9,none,none,none,none,none,most likely no additional sample,0,85,0,85,E3_E3,79.8,E3_E3,TRUE,Cohort 2,July,2017,not completed
TPAD0248,891,HC,0,0,4,D7,1.5 ml clear tube,2 ml Sarstedt low bind vial,500,4,7,no,E2,4_D2_2E,TPAD CSF Aliquots Batch4 Box6,E3-E9,1,71,0,Female,Cutpoint #1,21.1,159,0.14,761,5633,HC,HC,HC,none,none,most likely no additional sample,0,48.1,0,48.1,E3_E3,41.9,E3_E3,TRUE,Cohort 1,July,2017,not completed
TPAD0249,894,HC,0,0,2A,B4,vial,2 ml Sarstedt low bind vial,500,3,8,no,E1,4_D2_1A,TPAD CSF Aliquots Batch3 Box7,E2-E9,1,79,0,Female,Cutpoint #1,51,445.8,0.11,1231.3,10830.9,none,none,none,none,none,most likely no additional sample,53.7,5.8,76.8,136.3,E2_E4,128,E2_E4,TRUE,Cohort 2,August,2017,not completed
TPAD0250,895,HC,0,0,2A,B10,vial,2 ml Sarstedt low bind vial,500,3,8,no,D1,4_D2_1A,TPAD CSF Aliquots Batch3 Box7,D2-D9,1,81,1,Male,Cutpoint #1,45.3,340.8,0.09,1067.3,12447.9,none,none,none,none,none,most likely no additional sample,0,83.6,0,83.6,E3_E3,77.8,E3_E3,TRUE,Cohort 2,August,2017,not completed
TPAD0251,896,HC,0,0,2A,A8,vial,2 ml Sarstedt low bind vial,500,2,8,no,F1,4_D1_4B,TPAD CSF Aliquots Batch2 Box8,F2-F9,1,81,1,Male,Cutpoint #1,80.7,501,0.06,689,11427,HC,HC,HC,HC,none,most likely no additional sample,0,92.3,0,92.3,E3_E3,90.3,E3_E3,TRUE,Cohort 1,October,2017,not completed
TPAD0252,897,HC,0,0,3A,C2,vial,2 ml Sarstedt low bind vial,500,3,7,no,I1,4_D1_5E,TPAD CSF Aliquots Batch3 Box6,I2-I7,1,76,0,Female,Cutpoint #1,38,287.8,0.1,1019.3,10411.9,none,none,none,none,none,most likely no additional sample,0,46.5,46.5,93,E3_E4,92.7,E3_E4,TRUE,Cohort 2,September,2017,not completed
TPAD0253,899,HC,0,0,4,C6,vial,2 ml Sarstedt low bind vial,500,2,8,no,E1,4_D1_3E,TPAD CSF Aliquots Batch2 Box6,E2-E9,1,78,0,Female,Cutpoint #1,44.4,377.8,0.12,1606.3,13360.9,none,none,none,none,none,most likely no additional sample,0,103.8,0,103.8,E3_E3,103,E3_E3,TRUE,Cohort 2,October,2017,not completed
TPAD0254,900,HC,0,0,5,A3,vial,2 ml Sarstedt low bind vial,500,2,8,no,F1,4_D1_3E,TPAD CSF Aliquots Batch2 Box6,F2-F9,1,69,1,Male,Cutpoint #1,41.5,377.8,0.12,1345.3,11161.9,none,none,none,none,none,most likely no additional sample,0,110.4,0,110.4,E3_E3,108.1,E3_E3,TRUE,Cohort 2,November,2017,not completed
TPAD0255,915,HC,0,0,1A,B11,1.5 ml clear tube,2 ml Sarstedt low bind vial,500,3,8,no,B1,4_D1_5D,TPAD CSF Aliquots Batch3 Box5,B2-B9,1,69,0,Female,Cutpoint #1,32.2,220,0.13,1700,12676,HC,HC,HC,none,none,most likely no additional sample,0,77.3,0,77.3,E3_E3,66.4,E3_E3,TRUE,Cohort 1,October,2017,not completed
TPAD0256,918,HC,0,0,1B,E2,vial,2 ml Sarstedt low bind vial,500,2,8,no,G1,4_D1_3E,TPAD CSF Aliquots Batch2 Box6,G2-G9,1,64,1,Male,Cutpoint #1,40.2,262.8,0.13,1412.3,10947.9,none,none,none,none,none,most likely no additional sample,0,43.5,60.9,104.4,E3_E4,93.5,E3_E4,TRUE,Cohort 2,November,2017,not completed
TPAD0257,919,HC,0,0,3A,C1,vial,2 ml Sarstedt low bind vial,500,3,8,no,B1,4_D2_1A,TPAD CSF Aliquots Batch3 Box7,B2-B9,1,65,1,Male,Cutpoint #1,27,206.8,0.13,860.3,6449.9,none,none,none,none,none,most likely no additional sample,0,52.6,0,52.6,E3_E3,51.8,E3_E3,TRUE,Cohort 2,October,2017,not completed
TPAD0258,920,HC,0,0,4,B3,vial,2 ml Sarstedt low bind vial,500,3,8,no,E1,4_D1_5E,TPAD CSF Aliquots Batch3 Box6,E2-E9,1,65,1,Male,Cutpoint #1,28.8,310.8,0.13,797.3,6259.9,none,none,none,none,none,most likely no additional sample,21,25.3,0,46.3,E2_E3,45.2,na,FALSE,Cohort 2,October,2017,not completed
TPAD0259,924,HC,0,0,5,C8,vial,2 ml Sarstedt low bind vial,500,2,8,no,A1,4_D1_3E,TPAD CSF Aliquots Batch2 Box6,A2-A9,1,65,0,Female,Cutpoint #1,39.5,300.8,0.08,875.3,11462.9,none,none,none,none,none,most likely no additional sample,0,37.1,49.9,86.9,E3_E4,77.6,E3_E4,TRUE,Cohort 2,December,2017,not completed
TPAD0260,925,HC,0,0,5,B3,vial,2 ml Sarstedt low bind vial,500,4,8,no,G1,4_D2_3B,TPAD CSF Aliquots Batch4 Box8,G2-G9,1,67,0,Female,Cutpoint #1,30.8,276.8,0.13,1050.3,8130.9,none,none,none,none,none,most likely no additional sample,0,85.3,0,85.3,E3_E3,77,E3_E3,TRUE,Cohort 2,November,2017,not completed
TPAD0261,929,HC,0,0,3A,A2,vial,2 ml Sarstedt low bind vial,500,4,8,no,E1,4_D2_3B,TPAD CSF Aliquots Batch4 Box8,E2-E9,1,73,0,Female,Cutpoint #1,31.5,384.8,0.12,1146.3,9949.9,none,none,none,none,none,most likely no additional sample,0,78,0,78,E3_E3,70.5,E3_E3,TRUE,Cohort 2,December,2017,not completed
TPAD0262,932,AD,1,0,3A,B1,vial,2 ml Sarstedt low bind vial,500,3,8,no,B1,4_D2_1B,TPAD CSF Aliquots Batch3 Box8,B2-B9,2,57,0,Female,Cutpoint #1,174.6,1161,0.06,551,9689,AD,AD,AD,none,none,additional sample possibly available,0,58.1,63.3,121.5,E3_E4,118.6,E3_E4,TRUE,Cohort 1,December,2017,not completed
TPAD0263,934,HC,0,0,2A,C5,vial,2 ml Sarstedt low bind vial,500,2,8,no,H1,4_D1_3E,TPAD CSF Aliquots Batch2 Box6,H2-H9,1,63,1,Male,Cutpoint #1,38.5,323.8,0.13,1136.3,8700.9,none,none,none,none,none,most likely no additional sample,0,69.8,0,69.8,E3_E3,65.9,E3_E3,TRUE,Cohort 2,November,2017,not completed
TPAD0264,937,HC,0,0,2B,E1,vial,2 ml Sarstedt low bind vial,500,3,8,no,G1,4_D1_5E,TPAD CSF Aliquots Batch3 Box6,G2-G9,1,75,1,Male,Cutpoint #1,91,546.8,0.07,951.3,13156.9,none,none,none,none,none,most likely no additional sample,0,75.3,85.3,160.6,E3_E4,148.8,E3_E4,TRUE,Cohort 2,January,2018,not completed
TPAD0265,939,HC,0,0,2A,A11,vial,2 ml Sarstedt low bind vial,500,3,8,no,F1,4_D1_5E,TPAD CSF Aliquots Batch3 Box6,F2-F9,1,78,1,Male,Cutpoint #1,46.3,297.8,0.07,630.3,8874.9,none,none,none,none,none,most likely no additional sample,0,82,0,82,E3_E3,66.1,E3_E3,TRUE,Cohort 2,January,2018,not completed
TPAD0266,942,AD,1,0,1B,H9,vial,2 ml Sarstedt low bind vial,500,3,8,no,G1,4_D2_1B,TPAD CSF Aliquots Batch3 Box8,G2-G9,2,61,1,Male,Cutpoint #1,22.5,220,0.14,846,6100,AD,AD,AD,none,none,most likely no additional sample,0,82.3,0,82.3,E3_E3,75.7,E3_E3,TRUE,Cohort 1,October,2017,not completed
TPAD0267,945,HC,0,0,1B,F12,vial,2 ml Sarstedt low bind vial,500,3,8,no,H1,4_D1_5E,TPAD CSF Aliquots Batch3 Box6,H2-H9,1,68,1,Male,Cutpoint #1,43.4,326.8,0.11,1337.3,12407.9,none,none,none,none,none,additional sample possibly available,45.1,55.8,0,100.9,E2_E3,94.8,E2_E3,TRUE,Cohort 2,February,2018,not completed
TPAD0268,948,PD-noMCI,0,1,4,C2,vial,2 ml Sarstedt low bind vial,500,4,8,no,H1,4_D2_3D,TPAD CSF Aliquots Batch4 Box10,H2-H9,3,74,0,Female,Cutpoint #1,32.9,215,0.13,1253,9878,PD-noMCI,PD-noMCI,PD-noMCI,PD-noMCI,none,most likely no additional sample,0,99.2,0,99.2,E3_E3,93,E3_E3,TRUE,Cohort 1,January,2018,not completed
TPAD0269,951,PD-noMCI,0,1,1B,G7,vial,2 ml Sarstedt low bind vial,500,2,8,no,G1,4_D1_4C,TPAD CSF Aliquots Batch2 Box9,G2-G9,3,74,0,Female,Cutpoint #1,24.3,360,0.14,1137,8302,PD-noMCI,PD-noMCI,PD-noMCI,none,none,additional sample possibly available,0,99.5,0,99.5,E3_E3,95.3,E3_E3,TRUE,Cohort 1,January,2018,not completed
TPAD0270,956,HC,0,0,3B,F7,vial,2 ml Sarstedt low bind vial,500,2,8,no,B1,4_D1_3E,TPAD CSF Aliquots Batch2 Box6,B2-B9,1,66,1,Male,Cutpoint #1,42.8,324.8,0.09,1019.3,10967.9,none,none,none,none,none,additional sample possibly available,0,32.4,39.3,71.7,E3_E4,65,na,FALSE,Cohort 2,February,2018,not completed
TPAD0271,957,HC,0,0,1B,F6,vial,2 ml Sarstedt low bind vial,500,2,8,no,C1,4_D1_3E,TPAD CSF Aliquots Batch2 Box6,C2-C9,1,63,0,Female,Cutpoint #1,19.4,169.8,0.15,689.3,4680.9,none,none,none,none,none,most likely no additional sample,0,35.1,0,35.1,E3_E3,32,E3_E3,TRUE,Cohort 2,January,2018,not completed
TPAD0272,958,HC,0,0,1A,C10,vial,2 ml Sarstedt low bind vial,500,4,8,no,F1,4_D2_3B,TPAD CSF Aliquots Batch4 Box8,F2-F9,1,75,1,Male,Cutpoint #1,31.6,297.8,0.11,913.3,8349.9,none,none,none,none,none,additional sample possibly available,0,51.6,0,51.6,E3_E3,48.7,E3_E3,TRUE,Cohort 2,March,2018,not completed
TPAD0273,961,MCI,1,0,2A,D6,vial,2 ml Sarstedt low bind vial,500,2,7,no,D1,4_D1_4B,TPAD CSF Aliquots Batch2 Box8,D2-D8,2,64,1,Male,Cutpoint #1,99.4,576,0.05,470,10419,MCI,MCI,MCI,none,none,additional sample possibly available,0,48.8,61.6,110.4,E3_E4,122.7,E3_E4,TRUE,Cohort 1,November,2017,not completed
TPAD0274,962,HC,0,0,5,A4,vial,2 ml Sarstedt low bind vial,500,2,8,no,D1,4_D1_3E,TPAD CSF Aliquots Batch2 Box6,D2-D9,1,79,0,Female,Cutpoint #1,116.3,796.8,0.06,1122.3,18054.9,none,none,none,none,none,additional sample possibly available,0,108.7,0,108.7,E3_E3,114.8,na,FALSE,Cohort 2,March,2018,not completed
TPAD0275,963,HC,0,0,1A,D9,vial,2 ml Sarstedt low bind vial,500,4,8,no,D1,4_D2_3B,TPAD CSF Aliquots Batch4 Box8,D2-D9,1,76,1,Male,Cutpoint #1,106.5,692.8,0.05,778.3,16910.9,none,none,none,none,none,additional sample most likely available,0,60.6,92.7,153.3,E3_E4,142.6,na,FALSE,Cohort 2,February,2018,not completed
TPAD0276,967,Other,2,2,3A,C8,1.5 ml clear tube,2 ml Sarstedt low bind vial,500,2,8,no,D1,4_D1_3C,TPAD CSF Aliquots Batch2 Box4,D2-D9,3,62,0,Female,Cutpoint #1,70.4,488,0.09,1251,14095,PD-noMCI,PD-MCI,none,none,none,additional sample possibly available,0,148,0,148,E3_E3,145,E3_E3,TRUE,Cohort 1,February,2018,not completed
TPAD0277,970,HC,0,0,3A,A7,1.5 ml clear tube,2 ml Sarstedt low bind vial,500,2,8,no,C1,4_D1_3C,TPAD CSF Aliquots Batch2 Box4,C2-C9,1,69,1,Male,Cutpoint #1,23.7,247,0.1,821,8204,HC,HC,HC,none,none,additional sample possibly available,0,0,76.1,75.6,E4_E4,60.9,E4_E4,TRUE,Cohort 1,December,2017,not completed
TPAD0278,977,HC,0,0,1A,A11,vial,2 ml Sarstedt low bind vial,500,4,7,no,B1,4_D2_3B,TPAD CSF Aliquots Batch4 Box8,B2-B8,1,66,0,Female,Cutpoint #1,46.7,334.8,0.14,1490.3,11024.9,none,none,none,none,none,additional sample possibly available,0,72.7,0,72.7,E3_E3,74.2,E3_E3,TRUE,Cohort 2,March,2018,not completed
TPAD0279,978,HC,0,0,3B,G1,vial,2 ml Sarstedt low bind vial,500,4,8,no,C9,4_D2_3C,TPAD CSF Aliquots Batch4 Box9,D1-D8,1,71,0,Female,Cutpoint #1,41.3,310,0.06,549,9865,HC,HC,HC,none,none,additional sample possibly available,0,2.4,92.4,94.9,E4_E4,88.7,E4_E4,TRUE,Cohort 1,March,2018,not completed
TPAD0280,981,HC,0,0,4,C3,vial,2 ml Sarstedt low bind vial,500,3,8,no,A1,4_D1_5E,TPAD CSF Aliquots Batch3 Box6,A2-A9,1,68,0,Female,Cutpoint #1,24.3,198.8,0.13,948.3,7204.9,none,none,none,none,none,additional sample possibly available,0,64.6,0,64.6,E3_E3,57.1,E3_E3,TRUE,Cohort 2,April,2018,not completed
TPAD0281,982,HC,0,0,1B,H11,vial,2 ml Sarstedt low bind vial,500,2,8,no,I1,4_D1_3D,TPAD CSF Aliquots Batch2 Box5,I2-I9,1,67,0,Female,Cutpoint #1,21.9,237.8,0.12,712.3,5702.9,none,none,none,none,none,additional sample most likely available,0,20.6,27.2,47.8,E3_E4,45,E3_E4,TRUE,Cohort 2,March,2018,not completed
TPAD0282,983,PD-noMCI,0,1,1A,B10,vial,2 ml Sarstedt low bind vial,500,4,8,no,E9,4_D2_3C,TPAD CSF Aliquots Batch4 Box9,F1-F8,3,68,1,Male,Cutpoint #1,24.3,229,0.13,907,6755,PD-noMCI,PD-noMCI,PD-noMCI,none,none,additional sample possibly available,0,55.8,0,55.8,E3_E3,53.3,E3_E3,TRUE,Cohort 1,January,2018,not completed
TPAD0283,984,PD-noMCI,0,1,3B,H7,vial,2 ml Sarstedt low bind vial,500,4,8,no,A1,4_D2_3D,TPAD CSF Aliquots Batch4 Box10,A2-A9,3,79,0,Female,Cutpoint #1,56.6,399,0.15,2295,15365,PD-noMCI,PD-noMCI,PD-noMCI,none,none,additional sample possibly available,0,130.3,0,130.3,E3_E3,124.3,E3_E3,TRUE,Cohort 1,March,2018,not completed
TPAD0284,985,HC,0,0,4,A7,vial,2 ml Sarstedt low bind vial,500,2,8,no,H1,4_D1_3D,TPAD CSF Aliquots Batch2 Box5,H2-H9,1,72,0,Female,Cutpoint #1,59.2,499.8,0.13,1821.3,14138.9,none,none,none,none,none,additional sample most likely available,0,93.3,0,93.3,E3_E3,96.3,E3_E3,TRUE,Cohort 2,March,2018,not completed
TPAD0285,987,HC,0,0,3A,C9,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,E1,4_D1_2B,TPAD CSF Aliquots Batch1 Box7,E2-E8,1,72,1,Male,Cutpoint #1,33.7,259.8,0.11,1082.3,9706.9,none,none,none,none,none,additional sample most likely available,0,95.3,0,95.3,E3_E3,80.3,E3_E3,TRUE,Cohort 2,May,2018,not completed
TPAD0286,989,HC,0,0,5,A1,vial,2 ml Sarstedt low bind vial,500,2,8,no,A1,4_D1_4D,TPAD CSF Aliquots Batch2 Box10,A2-A9,1,67,0,Female,Cutpoint #1,92.1,630,0.05,595,11791,HC,HC,HC,none,none,additional sample possibly available,0,0.5,121.4,121.9,E4_E4,118.7,E4_E4,TRUE,Cohort 1,February,2018,not completed
TPAD0287,990,HC,0,0,2B,H1,1.5 ml clear tube,2 ml Sarstedt low bind vial,500,4,8,no,I1,4_D2_2E,TPAD CSF Aliquots Batch4 Box6,I2-I9,1,75,0,Female,Cutpoint #1,30.4,191,0.14,992,7185,HC,HC,HC,none,none,most likely no additional sample,0,82.6,0,82.6,E3_E3,77.6,E3_E3,TRUE,Cohort 1,February,2018,not completed
TPAD0288,992,HC,0,0,3B,G8,vial,2 ml Sarstedt low bind vial,500,4,8,no,C1,4_D2_3B,TPAD CSF Aliquots Batch4 Box8,C2-C9,1,68,1,Male,Cutpoint #1,31.9,280.8,0.11,1085.3,9515.9,none,none,none,none,none,most likely no additional sample,0,70.9,0,70.9,E3_E3,67.6,E3_E3,TRUE,Cohort 2,May,2018,not completed
TPAD0289,994,HC,0,0,5,E1,1.5 ml clear tube,2 ml Sarstedt low bind vial,500,4,8,no,H1,4_D2_2E,TPAD CSF Aliquots Batch4 Box6,H2-H9,1,69,1,Male,Cutpoint #1,42.5,265,0.08,663,8460,HC,HC,HC,none,none,most likely no additional sample,0,51.4,63.4,114.8,E3_E4,102.8,E3_E4,TRUE,Cohort 1,February,2018,not completed
TPAD0290,995,HC,0,0,1B,H4,vial,2 ml Sarstedt low bind vial,500,3,8,no,B1,4_D1_5E,TPAD CSF Aliquots Batch3 Box6,B2-B9,1,66,1,Male,Cutpoint #1,41.6,319.8,0.12,1625.3,13848.9,none,none,none,none,none,additional sample possibly available,0,121,0,121,E3_E3,104.2,E3_E3,TRUE,Cohort 2,April,2018,not completed
TPAD0291,1000,HC,0,0,3A,D2,vial,2 ml Sarstedt low bind vial,500,3,8,no,C1,4_D1_5E,TPAD CSF Aliquots Batch3 Box6,C2-C9,1,66,0,Female,Cutpoint #1,40,315.8,0.12,1386.3,11983.9,none,none,none,none,none,additional sample possibly available,40,49.7,0,89.7,E2_E3,82.3,E2_E3,TRUE,Cohort 2,May,2018,not completed
TPAD0292,1001,AD,1,0,3A,B9,vial,2 ml Sarstedt low bind vial,500,4,8,no,B9,4_D2_3C,TPAD CSF Aliquots Batch4 Box9,C1-C8,2,70,0,Female,Cutpoint #1,98.5,771,0.09,479,5287,AD,AD,none,none,none,additional sample possibly available,0,0,100.9,99.4,E4_E4,92.1,E4_E4,TRUE,Cohort 1,March,2018,not completed
TPAD0293,1004,HC,0,0,2B,E10,vial,2 ml Sarstedt low bind vial,500,2,8,no,G1,4_D1_3D,TPAD CSF Aliquots Batch2 Box5,G2-G9,1,74,1,Male,Cutpoint #1,39.9,295.8,0.12,1177.3,9598.9,none,none,none,none,none,additional sample possibly available,0,93.1,0,93.1,E3_E3,88.7,E3_E3,TRUE,Cohort 2,May,2018,not completed
TPAD0294,1006,HC,0,0,5,C11,vial,2 ml Sarstedt low bind vial,500,3,8,no,D1,4_D1_5E,TPAD CSF Aliquots Batch3 Box6,D2-D9,1,69,0,Female,Cutpoint #1,37.6,278.8,0.13,1276.3,9823.9,none,none,none,none,none,additional sample most likely available,0,73.5,0,73.5,E3_E3,71.5,E3_E3,TRUE,Cohort 2,May,2018,not completed
TPAD0295,1007,HC,0,0,5,B5,1.5 ml clear tube,2 ml Sarstedt low bind vial,500,2,8,no,E9,4_D1_3C,TPAD CSF Aliquots Batch2 Box4,F1-F8,1,62,0,Female,Cutpoint #1,21.8,139,0.12,1023,8816,HC,HC,none,none,none,most likely no additional sample,0,23,28,51,E3_E4,50.5,E3_E4,TRUE,Cohort 1,April,2018,not completed
TPAD0296,1010,HC,0,0,1B,G3,1.5 ml clear tube,2 ml Sarstedt low bind vial,500,3,8,no,C1,4_D1_5D,TPAD CSF Aliquots Batch3 Box5,C2-C9,1,73,0,Female,Cutpoint #1,34.1,201,0.05,397,8766,HC,HC,HC,none,none,additional sample possibly available,0,0.1,92.3,92.4,E4_E4,74.9,E4_E4,TRUE,Cohort 1,March,2018,not completed
TPAD0297,1012,PD-noMCI,0,1,3B,H4,vial,2 ml Sarstedt low bind vial,500,4,8,no,D9,4_D2_3C,TPAD CSF Aliquots Batch4 Box9,E1-E8,3,65,0,Female,Cutpoint #1,21.5,258,0.14,796,5726,PD-noMCI,PD-noMCI,PD-noMCI,none,none,additional sample most likely available,0,37.4,45.8,83.2,E3_E4,68.4,E3_E4,TRUE,Cohort 1,April,2018,SSA positive
TPAD0298,1013,PD-noMCI,0,1,4,D1,vial,2 ml Sarstedt low bind vial,500,2,8,no,E1,4_D1_4B,TPAD CSF Aliquots Batch2 Box8,E2-E9,3,77,1,Male,Cutpoint #1,28.4,330,0.08,543,7180,PD-noMCI,PD-noMCI,none,none,none,additional sample most likely available,0,28.8,39.6,68.4,E3_E4,72,E3_E4,TRUE,Cohort 1,May,2018,SSA negative
TPAD0299,1014,HC,0,0,1B,G1,vial,1.5 ml Eppendorf low bind tube,500,1,7,no,D1,4_D1_2B,TPAD CSF Aliquots Batch1 Box7,D2-D7,1,68,0,Female,Cutpoint #1,47.3,361.8,0.12,1707.3,14269.9,none,none,none,none,none,additional sample most likely available,0,113.3,0,113.3,E3_E3,101.1,E3_E3,TRUE,Cohort 2,May,2018,not completed
TPAD0300,1015,HC,0,0,4,A9,vial,2 ml Sarstedt low bind vial,500,3,8,no,A1,4_D2_1B,TPAD CSF Aliquots Batch3 Box8,A2-A9,1,65,1,Male,Cutpoint #1,48.3,293,0.07,689,10460,HC,HC,HC,none,none,additional sample possibly available,0,6.3,86.4,92.7,E4_E4,86.3,E4_E4,TRUE,Cohort 1,March,2018,not completed
TPAD0301,1016,HC,0,0,3B,E11,vial,2 ml Sarstedt low bind vial,500,4,8,no,A1,4_D2_3B,TPAD CSF Aliquots Batch4 Box8,A2-A9,1,65,0,Female,Cutpoint #1,37,271.8,0.11,1108.3,10263.9,none,none,none,none,none,additional sample possibly available,0,109.5,0,109.5,E3_E3,100.7,na,FALSE,Cohort 2,June,2018,not completed
TPAD0302,1018,HC,0,0,1A,D12,vial,1.5 ml Eppendorf low bind tube,500,1,7,no,C1,4_D1_2B,TPAD CSF Aliquots Batch1 Box7,C2-C7,1,68,0,Female,Cutpoint #1,30.7,269.8,0.11,898.3,7842.9,none,none,none,none,none,additional sample most likely available,0,35.5,37.4,72.9,E3_E4,66.3,E3_E4,TRUE,Cohort 2,June,2018,not completed
TPAD0303,1021,HC,0,0,5,E2,vial,2 ml Sarstedt low bind vial,500,3,8,no,A1,4_D2_1A,TPAD CSF Aliquots Batch3 Box7,A2-A9,1,63,0,Female,Cutpoint #1,33.7,265.8,0.13,1100.3,8600.9,none,none,none,none,none,additional sample most likely available,0,82.3,0,82.3,E3_E3,77,E3_E3,TRUE,Cohort 2,September,2018,not completed
TPAD0304,1024,PD-noMCI,0,1,3B,H8,vial,2 ml Sarstedt low bind vial,500,4,8,no,A9,4_D2_3C,TPAD CSF Aliquots Batch4 Box9,B1-B8,3,66,0,Female,Cutpoint #1,26.8,221,0.14,1432,10517,PD-noMCI,PD-noMCI,PD-noMCI,none,none,additional sample most likely available,0,64.8,0,64.8,E3_E3,57.2,E3_E3,TRUE,Cohort 1,April,2018,SSA positive
TPAD0305,1028,HC,0,0,1A,D7,1.5 ml clear tube,2 ml Sarstedt low bind vial,500,2,7,no,E1,4_D1_3C,TPAD CSF Aliquots Batch2 Box4,E2-E8,1,66,1,Male,Cutpoint #1,27.1,189,0.1,629,6564,HC,HC,HC,none,none,most likely no additional sample,0,65.8,0,65.8,E3_E3,63.4,E3_E3,TRUE,Cohort 1,March,2018,not completed
TPAD0306,1029,HC,0,0,3A,B12,vial,2 ml Sarstedt low bind vial,500,3,8,no,I1,4_D1_5D,TPAD CSF Aliquots Batch3 Box5,I2-I9,1,67,1,Male,Cutpoint #1,36.2,330.8,0.12,1121.3,9704.9,none,none,none,none,none,additional sample most likely available,0,89.5,0,89.5,E3_E3,86.5,E3_E3,TRUE,Cohort 2,June,2018,not completed
TPAD0307,1030,HC,0,0,3B,H5,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,H1,4_D1_2A,TPAD CSF Aliquots Batch1 Box6,H2-H8,1,66,0,Female,Cutpoint #1,63.2,478.8,0.13,1941.3,15198.9,none,none,none,none,none,additional sample most likely available,0,89.1,0,89.1,E3_E3,82.7,E3_E3,TRUE,Cohort 2,August,2018,not completed
TPAD0308,1031,HC,0,0,3B,E10,vial,2 ml Sarstedt low bind vial,500,2,8,no,F1,4_D1_3D,TPAD CSF Aliquots Batch2 Box5,F2-F9,1,78,1,Male,Cutpoint #1,72.7,595.8,0.09,1211.3,13726.9,none,none,none,none,none,additional sample possibly available,47.5,66.1,0,113.6,E2_E3,106.8,E2_E3,TRUE,Cohort 2,June,2018,not completed
TPAD0309,1034,AD,1,0,3B,E4,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,G1,4_D1_2B,TPAD CSF Aliquots Batch1 Box7,G2-G8,2,60,0,Female,Cutpoint #1,129.8,988,0.05,412,7743,AD,AD,none,none,none,additional sample most likely available,0,0.9,65.6,66.5,E4_E4,60.5,E4_E4,TRUE,Cohort 1,May,2018,SSA negative
TPAD0310,1035,Other,2,2,2A,C4,vial,2 ml Sarstedt low bind vial,500,2,8,no,H1,4_D1_4B,TPAD CSF Aliquots Batch2 Box8,H2-H9,3,73,1,Male,Cutpoint #1,63.7,444,0.07,945,13256,MCI,MCI,MCI,none,LBD primary; AD secondary; MCI amnestic multidomain and language,additional sample most likely available,0,100.7,0,100.7,E3_E3,94.8,E3_E3,TRUE,Cohort 1,November,2018,SSA positive
TPAD0311,1040,HC,0,0,2A,C9,vial,2 ml Sarstedt low bind vial,500,2,8,no,E1,4_D1_3D,TPAD CSF Aliquots Batch2 Box5,E2-E9,1,62,0,Female,Cutpoint #1,36.5,376.8,0.12,1256.3,10612.9,none,none,none,none,none,additional sample possibly available,32.9,37,0,69.9,E2_E3,64.5,na,FALSE,Cohort 2,August,2018,not completed
TPAD0312,1044,PD-noMCI,0,1,2A,A3,vial,2 ml Sarstedt low bind vial,500,3,8,no,F1,4_D2_1B,TPAD CSF Aliquots Batch3 Box8,F2-F9,3,63,1,Male,Cutpoint #1,30.5,191,0.12,980,7984,PD-noMCI,PD-noMCI,none,none,none,additional sample most likely available,0,108.1,0,108.1,E3_E3,113.6,E3_E3,TRUE,Cohort 1,May,2018,SSA positive
TPAD0313,1045,HC,0,0,2B,G3,vial,2 ml Sarstedt low bind vial,500,2,8,no,D1,4_D1_3D,TPAD CSF Aliquots Batch2 Box5,D2-D9,1,79,1,Male,Cutpoint #1,89.8,600.8,0.06,954.3,14817.9,none,none,none,none,none,additional sample most likely available,0,0,99.9,98.7,E4_E4,84.7,E4_E4,TRUE,Cohort 2,July,2018,not completed
TPAD0314,1047,HC,0,0,2B,H10,vial,2 ml Sarstedt low bind vial,500,4,8,no,H2,4_D2_3A,TPAD CSF Aliquots Batch4 Box7,H3-I1,1,65,0,Female,Cutpoint #1,23.9,218.8,0.11,574.3,5140.9,none,none,none,none,none,additional sample most likely available,0,17.2,18.2,35.4,E3_E4,33.4,E3_E4,TRUE,Cohort 2,October,2018,not completed
TPAD0315,1052,AD,1,0,2A,A4,vial,2 ml Sarstedt low bind vial,500,2,8,no,A1,4_D1_4C,TPAD CSF Aliquots Batch2 Box9,A2-A9,2,71,0,Female,Cutpoint #1,81.3,528,0.07,561,8424,AD,AD,AD,none,none,most likely no additional sample,0,37.2,44.1,81.4,E3_E4,80,E3_E4,TRUE,Cohort 1,July,2018,SSA negative
TPAD0316,1065,HC,0,0,3B,H9,0.5 ml blue tube,2 ml Sarstedt low bind vial,500,3,8,no,D1,4_D1_5D,TPAD CSF Aliquots Batch3 Box5,D2-D9,1,65,0,Female,Cutpoint #1,31.6,1109.8,0.13,1010.3,7711.9,none,none,none,none,none,additional sample most likely available,0,32.8,41.4,74.2,E3_E4,71.2,E3_E4,TRUE,Cohort 2,December,2018,not completed
TPAD0317,1067,HC,0,0,4,B8,vial,2 ml Sarstedt low bind vial,500,2,8,no,C1,4_D1_3D,TPAD CSF Aliquots Batch2 Box5,C2-C9,1,67,0,Female,Cutpoint #1,32.9,276.8,0.12,1217.3,10494.9,none,none,none,none,none,additional sample most likely available,0,73.1,0,73.1,E3_E3,73.7,na,FALSE,Cohort 2,September,2018,not completed
TPAD0318,1072,PD-noMCI,0,1,1A,B5,vial,2 ml Sarstedt low bind vial,500,3,8,no,C1,4_D2_1B,TPAD CSF Aliquots Batch3 Box8,C2-C9,3,71,1,Male,Cutpoint #1,34.7,298,0.15,1515,10404,PD-noMCI,PD-noMCI,PD-noMCI,none,none,additional sample most likely available,40.4,0,56.4,95.6,E2_E4,83,E2_E4,TRUE,Cohort 1,September,2018,SSA positive
TPAD0319,1077,HC,0,0,2B,F7,vial,2 ml Sarstedt low bind vial,500,4,8,no,D2,4_D2_3A,TPAD CSF Aliquots Batch4 Box7,D3-E1,1,73,1,Male,Cutpoint #1,41.1,291.8,0.12,1319.3,11167.9,none,none,none,none,none,additional sample most likely available,0,91.7,0,91.7,E3_E3,81.3,E3_E3,TRUE,Cohort 2,October,2018,not completed
TPAD0320,1078,MCI,1,0,1A,A2,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,B1,4_D1_2C,TPAD CSF Aliquots Batch1 Box8,B2-B8,2,83,0,Female,Cutpoint #1,67.8,456,0.07,926,13142,MCI,MCI,none,none,none,additional sample most likely available,0,111.1,0,111.1,E3_E3,112.5,E3_E3,TRUE,Cohort 1,August,2018,SSA negative
TPAD0321,1080,HC,0,0,2A,C6,vial,2 ml Sarstedt low bind vial,500,4,8,no,E2,4_D2_3A,TPAD CSF Aliquots Batch4 Box7,E3-F1,1,64,0,Female,Cutpoint #1,30,207.8,0.12,967.3,8400.9,none,none,none,none,none,additional sample most likely available,0,35.1,40.4,75.5,E3_E4,75.3,E3_E4,TRUE,Cohort 2,October,2018,not completed
TPAD0322,1083,HC,0,0,2A,A5,vial,2 ml Sarstedt low bind vial,500,4,8,no,F2,4_D2_3A,TPAD CSF Aliquots Batch4 Box7,F3-G1,1,73,1,Male,Cutpoint #1,71.3,483.8,0.07,1069.3,15975.9,none,none,none,none,none,additional sample most likely available,0,71,77.4,148.4,E3_E4,147.2,E3_E4,TRUE,Cohort 2,December,2018,not completed
TPAD0323,1084,LBD,2,2,3A,A9,vial,2 ml Sarstedt low bind vial,500,3,8,no,H1,4_D2_1B,TPAD CSF Aliquots Batch3 Box8,H2-H9,3,58,1,Male,Cutpoint #1,71.7,502,0.07,583,8425,LBD,LBD,none,none,none,additional sample most likely available,0,37.2,49,86.1,E3_E4,83.3,E3_E4,TRUE,Cohort 1,July,2018,SSA positive
TPAD0324,1088,PD-MCI,1,1,3A,B2,vial,2 ml Sarstedt low bind vial,500,3,8,no,C1,4_D2_1C,TPAD CSF Aliquots Batch3 Box9,C2-C9,3,79,1,Male,Cutpoint #1,19.2,283,0.14,918,6665,PD-MCI,PD-MCI,none,none,none,additional sample most likely available,0,74.3,0,74.3,E3_E3,70.6,E3_E3,TRUE,Cohort 1,December,2018,SSA negative
TPAD0325,1091,MCI,1,0,1A,B9,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,H1,4_D1_2B,TPAD CSF Aliquots Batch1 Box7,H2-H8,2,78,1,Male,Cutpoint #1,54,367,0.06,460,7580,MCI,MCI,none,none,none,additional sample most likely available,0,86.3,0,86.3,E3_E3,74.9,E3_E3,TRUE,Cohort 1,September,2018,SSA negative
TPAD0326,1095,HC,0,0,5,D4,vial,1.5 ml Eppendorf low bind tube,500,1,7,no,B1,4_D1_2B,TPAD CSF Aliquots Batch1 Box7,B2-B7,1,67,1,Male,Cutpoint #1,37.7,267.8,0.09,977.3,10715.9,none,none,none,none,none,additional sample most likely available,0,100.9,0,100.9,E3_E3,99.5,E3_E3,TRUE,Cohort 2,December,2018,not completed
TPAD0327,1096,HC,0,0,2B,E11,vial,2 ml Sarstedt low bind vial,500,4,8,no,G2,4_D2_3A,TPAD CSF Aliquots Batch4 Box7,G3-H1,1,89,1,Male,Cutpoint #1,34.5,267.8,0.11,759.3,7041.9,none,none,none,none,none,additional sample most likely available,0,30.3,31.5,61.8,E3_E4,56.3,na,FALSE,Cohort 2,November,2018,not completed
TPAD0328,1099,HC,0,0,2B,H3,0.5 ml blue tube,2 ml Sarstedt low bind vial,500,4,8,no,E8,4_D2_2C,TPAD CSF Aliquots Batch4 Box4,E9-F7,1,71,0,Female,Cutpoint #1,52.9,361.8,0.07,866.3,12316.9,none,none,none,none,none,additional sample most likely available,0,94.2,0,94.2,E3_E3,85.4,E3_E3,TRUE,Cohort 2,January,2019,not completed
TPAD0329,1101,HC,0,0,5,E8,0.5 ml pink tube,2 ml Sarstedt low bind vial,500,4,8,no,F8,4_D2_2C,TPAD CSF Aliquots Batch4 Box4,F9-G7,1,73,1,Male,Cutpoint #1,23.2,164.8,0.13,748.3,5591.9,none,none,none,none,none,additional sample most likely available,0,40.2,0,40.2,E3_E3,38.8,na,FALSE,Cohort 2,March,2019,not completed
TPAD0330,1105,HC,0,0,1B,F7,0.5 ml yellow tube,2 ml Sarstedt low bind vial,500,2,7,no,C2,4_D1_3B,TPAD CSF Aliquots Batch2 Box3,C3-C9,1,68,1,Male,Cutpoint #1,43.4,318.8,0.13,1488.3,11635.9,none,none,none,none,none,additional sample most likely available,0,41.1,60.7,101.8,E3_E4,97.4,na,FALSE,Cohort 2,February,2019,not completed
TPAD0331,1111,HC,0,0,2B,E4,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,I1,4_D1_2B,TPAD CSF Aliquots Batch1 Box7,I2-I8,1,70,0,Female,Cutpoint #1,26.2,217,0.13,1143,9078,HC,HC,none,none,none,additional sample most likely available,0,63.5,0,63.5,E3_E3,59.3,E3_E3,TRUE,Cohort 1,October,2018,SSA negative
TPAD0332,1113,HC,0,0,1A,D5,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,A1,4_D1_2C,TPAD CSF Aliquots Batch1 Box8,A2-A8,1,73,1,Male,Cutpoint #1,33.1,229,0.14,1155,8167,HC,HC,none,none,none,additional sample most likely available,34.1,34.2,0,68.3,E2_E3,57.5,E2_E3,TRUE,Cohort 1,October,2018,SSA negative
TPAD0333,1116,HC,0,0,1B,F10,vial,1.5 ml Eppendorf low bind tube,500,1,7,no,I1,4_D1_2B,TPAD CSF Aliquots Batch1 Box6,I2-I7,1,70,1,Male,Cutpoint #1,43.7,295.8,0.12,1206.3,10045.9,none,none,none,none,none,additional sample most likely available,0,104.8,0,104.8,E3_E3,99.5,E3_E3,TRUE,Cohort 2,January,2019,not completed
TPAD0334,1118,HC,0,0,2A,B3,vial,2 ml Sarstedt low bind vial,500,2,8,no,G1,4_D1_4B,TPAD CSF Aliquots Batch2 Box8,G2-G9,1,63,0,Female,Cutpoint #1,61.9,484,0.05,734,14070,HC,HC,none,none,none,additional sample possibly available,0,94.9,0,94.9,E3_E3,93.7,E3_E3,TRUE,Cohort 1,January,2019,not completed
TPAD0335,1120,AD,1,0,4,C12,vial,2 ml Sarstedt low bind vial,500,3,8,no,E1,4_D2_1B,TPAD CSF Aliquots Batch3 Box8,E2-E9,2,58,0,Female,Cutpoint #1,91.7,664,0.06,484,8720,AD,AD,none,none,none,additional sample possibly available,0,33.8,47.4,81.2,E3_E4,76.8,E3_E4,TRUE,Cohort 1,November,2018,SSA negative
TPAD0336,1126,Other,2,2,4,C11,vial,2 ml Sarstedt low bind vial,500,2,8,no,I1,4_D1_4B,TPAD CSF Aliquots Batch2 Box8,I2-I9,1,61,0,Female,Cutpoint #1,41.4,355,0.15,1924,12653,MCI,HC,none,none,FH of DLB,additional sample possibly available,45.7,59.9,0,105.6,E2_E3,96.2,E2_E3,TRUE,Cohort 1,December,2018,SSA negative
TPAD0337,1132,HC,0,0,3A,B8,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,D1,4_D1_2C,TPAD CSF Aliquots Batch1 Box8,D2-D8,1,73,0,Female,Cutpoint #1,35.2,231,0.1,892,9188,HC,HC,none,none,none,additional sample most likely available,0,30,34.3,64.2,E3_E4,63.8,na,FALSE,Cohort 1,December,2018,not completed
TPAD0338,1133,HC,0,0,5,D1,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,E1,4_D1_2C,TPAD CSF Aliquots Batch1 Box8,E2-E8,1,51,0,Female,Cutpoint #1,34.4,217,0.13,1384,10570,HC,none,none,none,none,additional sample most likely available,35.5,0,45.8,79.7,E2_E4,68.9,E2_E4,TRUE,Cohort 1,December,2018,SSA negative
TPAD0339,1145,Other,2,2,3B,F11,vial,2 ml Sarstedt low bind vial,500,2,8,no,C1,4_D1_4C,TPAD CSF Aliquots Batch2 Box9,C2-C9,2,78,1,Male,Cutpoint #1,45.4,340,0.13,1679,13225,HC,MCI,none,none,Y1: normal with concerns in cognition and movement (poss LBD); Y2: MCI amnestic multi domain + executive,additional sample possibly available,0,47.7,55.5,103.1,E3_E4,92.2,E3_E4,TRUE,Cohort 1,January,2019,SSA positive
TPAD0340,1148,HC,0,0,5,E3,vial,2 ml Sarstedt low bind vial,500,4,8,no,D2,4_D2_3D,TPAD CSF Aliquots Batch4 Box10,D3-E1,1,74,1,Male,Cutpoint #1,62,426,0.14,1893,13517,HC,HC,none,none,none,additional sample possibly available,0,133.5,0,133.5,E3_E3,117.2,E3_E3,TRUE,Cohort 1,March,2019,SSA negative
TPAD0341,1158,HC,0,0,5,E10,vial,2 ml Sarstedt low bind vial,500,3,8,no,D1,4_D2_1C,TPAD CSF Aliquots Batch3 Box9,D2-D9,1,54,1,Male,Cutpoint #1,26.6,374,0.13,1197,9155,HC,HC,none,none,none,additional sample possibly available,0,30.8,39.7,70.5,E3_E4,70.1,E3_E4,TRUE,Cohort 1,April,2019,SSA negative
TPAD0342,1163,HC,0,0,1A,A7,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,I1,4_D1_1E,TPAD CSF Aliquots Batch1 Box5,I2-I8,1,68,0,Female,Cutpoint #1,75.7,409.8,0.07,472.3,6468.9,none,none,none,none,none,additional sample most likely available,0,27.5,29.5,57,E3_E4,55.3,E3_E4,TRUE,Cohort 2,July,2019,not completed
TPAD0343,1167,HC,0,0,3A,D9,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,F1,4_D1_2B,TPAD CSF Aliquots Batch1 Box7,F2-F8,1,67,0,Female,Cutpoint #1,35.4,298,0.14,1778,12383,HC,HC,none,none,label =11677?,additional sample most likely available,0,45.1,50.6,95.7,E3_E4,81.9,E3_E4,TRUE,Cohort 1,May,2019,not completed
TPAD0344,1168,AD,1,0,4,C8,vial,2 ml Sarstedt low bind vial,500,4,8,no,E2,4_D2_3D,TPAD CSF Aliquots Batch4 Box10,E3-F1,2,81,0,Female,Cutpoint #1,81.2,524,0.05,396,7252,AD,AD,none,none,none,most likely no additional sample,43.7,0,65.3,108.7,E2_E4,96.8,E2_E4,TRUE,Cohort 1,March,2019,SSA negative
TPAD0345,1171,MCI,1,0,1B,G11,0.5 ml blue tube,1.5 ml Eppendorf low bind tube,500,1,8,no,F1,4_D1_1E,TPAD CSF Aliquots Batch1 Box5,F2-F8,2,78,1,Male,Cutpoint #1,28.6,219,0.14,1476,10471,MCI,MCI,none,none,none,additional sample most likely available,0,89.8,0,89.8,E3_E3,85.8,E3_E3,TRUE,Cohort 1,March,2019,SSA negative
TPAD0346,1174,HC,0,0,5,B6,vial,2 ml Sarstedt low bind vial,500,3,7,no,I1,4_D2_1B,TPAD CSF Aliquots Batch3 Box8,I2-I8,1,70,0,Female,Cutpoint #1,47,357,0.08,751,8856,HC,HC,none,none,none,additional sample possibly available,0,78.5,0,78.5,E3_E3,70,E3_E3,TRUE,Cohort 1,May,2019,not completed
TPAD0347,1175,HC,0,0,5,C9,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,C1,4_D1_2C,TPAD CSF Aliquots Batch1 Box8,C2-C8,1,70,1,Male,Cutpoint #1,40.1,1325,0.09,932,10654,HC,HC,none,none,none,additional sample most likely available,0,96.8,0,96.8,E3_E3,94.5,E3_E3,TRUE,Cohort 1,May,2019,SSA negative
TPAD0348,1179,HC,0,0,1A,B2,0.5 ml yellow tube,2 ml Sarstedt low bind vial,500,4,8,no,F1,4_D2_2E,TPAD CSF Aliquots Batch4 Box6,F2-F9,1,59,0,Female,Cutpoint #1,26.1,173,0.15,1545,10112,HC,none,none,none,none,additional sample possibly available,26.4,29.8,0,56.3,E2_E3,51.9,E2_E3,TRUE,Cohort 1,April,2019,SSA negative
TPAD0349,1180,HC,0,0,2A,B11,0.5 ml yellow tube,2 ml Sarstedt low bind vial,500,4,8,no,G1,4_D2_2E,TPAD CSF Aliquots Batch4 Box6,G2-G9,1,63,0,Female,Cutpoint #1,62.6,459,0.08,996,13239,HC,HC,none,none,none,additional sample most likely available,0,55.8,62.8,118.6,E3_E4,101,E3_E4,TRUE,Cohort 1,April,2019,SSA positive
TPAD0350,1181,Other,2,2,1B,F11,vial,2 ml Sarstedt low bind vial,500,3,8,no,B1,4_D2_1C,TPAD CSF Aliquots Batch3 Box9,B2-B9,3,71,1,Male,Cutpoint #1,24.1,540,0.08,323,4090,LBD,none,none,none,LBD primary; Secondary: possible Alzheimer's disease / R occipital stroke,additional sample most likely available,0,16.4,21.1,37.5,E3_E4,32.7,E3_E4,TRUE,Cohort 1,May,2019,SSA positive
TPAD0351,1182,HC,0,0,5,E9,vial,2 ml Sarstedt low bind vial,500,3,7,no,A1,4_D2_1C,TPAD CSF Aliquots Batch3 Box9,A2-A8,1,76,0,Female,Cutpoint #1,71.7,389,0.06,821,13744,HC,HC,none,none,none,additional sample possibly available,0,101.7,0,101.7,E3_E3,106.4,E3_E3,TRUE,Cohort 1,May,2019,not completed
TPAD0352,1185,HC,0,0,4,B6,vial,2 ml Sarstedt low bind vial,500,3,8,no,G1,4_D1_5D,TPAD CSF Aliquots Batch3 Box5,G2-G9,1,70,0,Female,Cutpoint #1,168.1,879.8,0.06,829.3,13403.9,none,none,none,none,none,additional sample most likely available,0,59.2,61,120.2,E3_E4,118.3,E3_E4,TRUE,Cohort 2,June,2019,not completed
TPAD0353,1187,LBD,2,2,1A,A9,vial,2 ml Sarstedt low bind vial,500,2,8,no,B1,4_D1_4C,TPAD CSF Aliquots Batch2 Box9,B2-B9,3,61,0,Female,Cutpoint #1,72,558,0.07,363,5415,LBD,LBD,none,none,none,additional sample possibly available,0,20,21.6,41.7,E3_E4,38.2,E3_E4,TRUE,Cohort 1,May,2019,SSA negative
TPAD0354,1189,HC,0,0,2A,C1,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,F1,4_D1_2C,TPAD CSF Aliquots Batch1 Box8,F2-F8,1,72,0,Female,Cutpoint #1,44,276,0.06,528,8396,HC,HC,none,none,none,additional sample most likely available,0,24.7,26.8,51.5,E3_E4,43.5,E3_E4,TRUE,Cohort 1,May,2019,not completed
TPAD0355,1190,HC,0,0,1A,C1,vial,2 ml Sarstedt low bind vial,500,4,8,no,B2,4_D2_3A,TPAD CSF Aliquots Batch4 Box7,B3-C1,1,69,0,Female,Cutpoint #1,37.7,369.8,0.11,1066.3,9426.9,none,none,none,none,none,additional sample most likely available,0,84.5,0,84.5,E3_E3,76.8,E3_E3,TRUE,Cohort 2,October,2019,not completed
TPAD0356,1192,HC,0,0,2B,H11,vial,2 ml Sarstedt low bind vial,500,2,8,no,B1,4_D1_3D,TPAD CSF Aliquots Batch2 Box5,B2-B9,1,65,0,Female,Cutpoint #1,31,310.8,0.11,914.3,8011.9,none,none,none,none,none,additional sample most likely available,0,77.5,0,77.5,E3_E3,69.3,E3_E3,TRUE,Cohort 2,November,2019,not completed
TPAD0357,1193,HC,0,0,4,D12,vial,2 ml Sarstedt low bind vial,500,4,8,no,C2,4_D2_3A,TPAD CSF Aliquots Batch4 Box7,C3-D1,1,63,0,Female,Cutpoint #1,42.8,298.8,0.09,711.3,8068.9,none,none,none,none,none,additional sample most likely available,0,38.8,43.3,82.1,E3_E4,75,E3_E4,TRUE,Cohort 2,September,2019,not completed
TPAD0358,1197,MCI,1,0,2B,H6,vial,1.5 ml Eppendorf low bind tube,500,1,7,no,G1,4_D1_2C,TPAD CSF Aliquots Batch1 Box8,G2-G7,2,79,1,Male,Cutpoint #1,23.1,362,0.13,1047,8214,MCI,none,none,none,none,additional sample most likely available,0,65.6,0,65.6,E3_E3,66.7,E3_E3,TRUE,Cohort 1,June,2019,SSA positive
TPAD0359,1200,HC,0,0,5,D7,vial,2 ml Sarstedt low bind vial,500,3,8,no,E1,4_D2_1C,TPAD CSF Aliquots Batch3 Box9,E2-E9,1,63,1,Male,Cutpoint #1,37.8,214,0.09,870,9300,HC,HC,none,none,none,additional sample possibly available,0,40.7,51.7,92.5,E3_E4,94.1,E3_E4,TRUE,Cohort 1,June,2019,not completed
TPAD0360,1201,HC,0,0,5,C7,vial,2 ml Sarstedt low bind vial,500,3,7,no,E1,4_D1_5D,TPAD CSF Aliquots Batch3 Box5,E2-E8,1,71,0,Female,Cutpoint #1,56.1,339.8,0.08,861.3,10654.9,none,none,none,none,none,additional sample most likely available,0,88.1,0,88.1,E3_E3,86.8,E3_E3,TRUE,Cohort 2,November,2019,not completed
TPAD0361,1205,AD,1,0,2A,B1,vial,1.5 ml Eppendorf low bind tube,500,1,7,no,H1,4_D1_2C,TPAD CSF Aliquots Batch1 Box8,H2-H7,2,63,0,Female,Cutpoint #1,147.4,882,0.07,898,12586,AD,AD,none,none,none,additional sample most likely available,0,52.4,59.7,112,E3_E4,99.9,E3_E4,TRUE,Cohort 1,June,2019,SSA negative
TPAD0362,1206,HC,0,0,3B,G7,vial,2 ml Sarstedt low bind vial,500,4,8,no,F2,4_D2_3D,TPAD CSF Aliquots Batch4 Box10,F3-G1,1,76,0,Female,Cutpoint #1,57.1,523.3,0.08,763.3,9887,HC,HC,none,none,none,additional sample most likely available,0,0,84.4,83.6,E4_E4,69.4,E4_E4,TRUE,Cohort 1,November,2019,not completed
TPAD0363,1207,HC,0,0,3A,A8,vial,1.5 ml Eppendorf low bind tube,500,1,7,no,D1,4_D1_2D,TPAD CSF Aliquots Batch1 Box9,D2-D7,1,78,1,Male,Cutpoint #1,67.1,423,0.08,1000,12425,HC,HC,none,none,none,additional sample most likely available,0,95.7,0,95.7,E3_E3,96.4,E3_E3,TRUE,Cohort 1,August,2019,SSA negative
TPAD0364,1208,HC,0,0,4,D4,vial,2 ml Sarstedt low bind vial,500,3,8,no,F1,4_D2_1C,TPAD CSF Aliquots Batch3 Box9,F2-F9,1,36,1,Male,Cutpoint #1,67.7,413,0.06,317,5547,HC,HC,none,none,none,additional sample possibly available,0,57.3,0,57.3,E3_E3,52.9,na,FALSE,Cohort 1,July,2019,not completed
TPAD0365,1209,HC,0,0,2B,G8,vial,2 ml Sarstedt low bind vial,500,2,8,no,D1,4_D1_4C,TPAD CSF Aliquots Batch2 Box9,D2-D9,1,72,1,Male,Cutpoint #1,36.8,440,0.11,700,6375,HC,HC,none,none,none,additional sample most likely available,0,78.2,0,78.2,E3_E3,68.1,E3_E3,TRUE,Cohort 1,July,2019,not completed
TPAD0366,1210,HC,0,0,1B,E10,vial,1.5 ml Eppendorf low bind tube,500,1,7,no,B1,4_D1_2D,TPAD CSF Aliquots Batch1 Box9,B2-B7,1,65,0,Female,Cutpoint #1,12.7,219,0.13,546,4339,HC,HC,none,none,none,additional sample most likely available,0,29.3,0,29.3,E3_E3,26.9,E3_E3,TRUE,Cohort 1,July,2019,not completed
TPAD0367,1211,MCI,1,0,1A,D1,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,I1,4_D1_2C,TPAD CSF Aliquots Batch1 Box8,I2-I8,2,74,0,Female,Cutpoint #1,85.3,533,0.06,647,10629,MCI,MCI,none,none,none,additional sample most likely available,0,36.5,40.5,77,E3_E4,75.7,E3_E4,TRUE,Cohort 1,July,2019,SSA negative
TPAD0368,1213,HC,0,0,4,C5,vial,2 ml Sarstedt low bind vial,500,3,8,no,I1,4_D2_1C,TPAD CSF Aliquots Batch3 Box9,I2-I9,1,80,1,Male,Cutpoint #1,38.5,302,0.14,1488,10970,HC,HC,none,none,none,additional sample possibly available,0,45.4,52.6,98,E3_E4,85.4,E3_E4,TRUE,Cohort 1,July,2019,SSA negative
TPAD0369,1220,Other,2,2,1B,F8,vial,2 ml Sarstedt low bind vial,500,2,8,no,F1,4_D1_4C,TPAD CSF Aliquots Batch2 Box9,F2-F9,2,79,0,Female,Cutpoint #1,33.7,215,0.13,1556,11817,MCI,MCI,none,none,MCI amnestic multi-domain & language (stroke contributing ?) vascular etiology since negative PET and AD CSF markers,additional sample possibly available,33.4,43,0,76.4,E2_E3,73.5,E2_E3,TRUE,Cohort 1,August,2019,SSA negative
TPAD0370,1222,PD-noMCI,0,1,4,A10,vial,2 ml Sarstedt low bind vial,500,4,7,no,G2,4_D2_3D,TPAD CSF Aliquots Batch4 Box10,G3-G9,3,62,1,Male,Cutpoint #1,27.4,147.3,0.12,900.3,7826,PD-noMCI,none,none,none,none,additional sample most likely available,0,39.2,52.1,91.3,E3_E4,93.4,E3_E4,TRUE,Cohort 1,October,2019,SSA positive
TPAD0371,1223,PD-noMCI,0,1,3B,E1,vial,2 ml Sarstedt low bind vial,500,2,8,no,B1,4_D1_4D,TPAD CSF Aliquots Batch2 Box10,B2-B9,3,77,0,Female,Cutpoint #1,53.4,349.3,0.07,711.3,10871,PD-noMCI,PD-noMCI,none,none,Y2: with concerns - need full cog testing next year,additional sample possibly available,0,46.1,52.6,98.7,E3_E4,85.9,E3_E4,TRUE,Cohort 1,October,2019,SSA positive
TPAD0372,1226,MCI,1,0,1B,E9,vial,1.5 ml Eppendorf low bind tube,500,1,7,no,G1,4_D1_2D,TPAD CSF Aliquots Batch1 Box9,G2-G7,2,70,1,Male,Cutpoint #1,83.5,450,0.07,825,12000,MCI,none,none,none,none,additional sample most likely available,0,86.4,0,86.4,E3_E3,86.3,E3_E3,TRUE,Cohort 1,August,2019,SSA negative
TPAD0373,1229,HC,0,0,1B,G10,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,E1,4_D1_2D,TPAD CSF Aliquots Batch1 Box9,E2-E8,1,69,0,Female,Cutpoint #1,48.4,392,0.13,1596,12716,HC,HC,none,none,none,additional sample most likely available,0,46.2,73.9,120.1,E3_E4,116.6,E3_E4,TRUE,Cohort 1,August,2019,SSA negative
TPAD0374,1230,HC,0,0,2A,B7,vial,2 ml Sarstedt low bind vial,500,2,7,no,H7,4_D1_3C,TPAD CSF Aliquots Batch2 Box4,H8-I5,1,67,1,Male,Cutpoint #1,37.4,281.8,0.12,1150.3,9300.9,none,none,none,none,none,additional sample most likely available,0,71.9,0,71.9,E3_E3,61.5,E3_E3,TRUE,Cohort 2,November,2019,not completed
TPAD0375,1231,HC,0,0,3B,G10,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,H1,4_D1_1E,TPAD CSF Aliquots Batch1 Box5,H2-H8,1,67,0,Female,Cutpoint #1,59,409.8,0.13,1598.3,12370.9,none,none,none,none,none,additional sample most likely available,0,39.6,47.3,87,E3_E4,77.2,E3_E4,TRUE,Cohort 2,January,2020,not completed
TPAD0376,1232,PD-noMCI,0,1,1A,B12,vial,2 ml Sarstedt low bind vial,500,4,9,no,B1,4_D2_3E,TPAD CSF Aliquots Batch4 Box11,B2-C1,3,67,0,Female,Cutpoint #1,30.3,353.3,0.12,1167.3,9601,PD-noMCI,PD-noMCI,none,none,none,additional sample most likely available,0,100.5,0,100.5,E3_E3,88.8,E3_E3,TRUE,Cohort 1,October,2019,SSA positive
TPAD0377,1236,AD,1,0,3B,G6,vial,1.5 ml Eppendorf low bind tube,500,1,7,no,H1,4_D1_2D,TPAD CSF Aliquots Batch1 Box9,H2-H7,2,82,0,Female,Cutpoint #1,113.9,776.3,0.07,638.3,9806,AD,AD,none,none,AD pathology primary LBD contributing,additional sample most likely available,0,27.7,34.8,62.5,E3_E4,60.6,E3_E4,TRUE,Cohort 1,September,2019,SSA negative
TPAD0378,1237,AD,1,0,2B,H4,vial,1.5 ml Eppendorf low bind tube,500,1,7,no,C1,4_D1_2D,TPAD CSF Aliquots Batch1 Box9,C2-C7,2,73,1,Male,Cutpoint #1,397.9,1926.3,0.04,624.3,14096,AD,AD,none,none,none,additional sample most likely available,0,0,129.3,126.4,E4_E4,125.9,E4_E4,TRUE,Cohort 1,September,2019,SSA positive
TPAD0379,1241,AD,1,0,1A,B4,vial,2 ml Sarstedt low bind vial,500,3,7,no,G1,4_D2_1C,TPAD CSF Aliquots Batch3 Box9,G2-G8,2,76,0,Female,Cutpoint #1,96.9,658.3,0.07,842.3,12306,AD,AD,none,none,none,additional sample most likely available,0,67.1,84.1,151.2,E3_E4,138,E3_E4,TRUE,Cohort 1,October,2019,SSA negative
TPAD0380,1243,PD-noMCI,0,1,4,B7,vial,2 ml Sarstedt low bind vial,500,2,8,no,E1,4_D1_4C,TPAD CSF Aliquots Batch2 Box9,E2-E9,3,69,1,Male,Cutpoint #1,29.8,174.3,0.12,1148.3,9654,PD-noMCI,PD-noMCI,none,none,Y2: with concerns in executive function,additional sample most likely available,0,38.7,48.5,87.2,E3_E4,95.5,E3_E4,TRUE,Cohort 1,October,2019,SSA positive
TPAD0381,1245,MCI,1,0,4,B4,vial,2 ml Sarstedt low bind vial,500,3,7,no,A1,4_D2_1D,TPAD CSF Aliquots Batch3 Box10,A2-A8,2,45,1,Male,Cutpoint #1,29.7,207.3,0.12,944.3,7743,MCI,MCI,none,none,PSEN mutation; MCI amnestic multidomain executive and visuospatial,additional sample most likely available,0,72.7,0,72.7,E3_E3,68.4,E3_E3,TRUE,Cohort 1,November,2019,SSA negative
TPAD0382,1248,Other,2,2,1B,G5,vial,2 ml Sarstedt low bind vial,500,2,7,no,I1,4_D1_4C,TPAD CSF Aliquots Batch2 Box9,I2-I8,2,82,0,Female,Cutpoint #1,270.8,1838.3,0.05,788.3,15575,HC,MCI,none,none,MCI amnestic multidomain and visuospatial,additional sample most likely available,0,85.3,104.5,189.8,E3_E4,167.4,E3_E4,TRUE,Cohort 1,October,2019,not completed
TPAD0383,1251,AD,1,0,2B,F3,vial,2 ml Sarstedt low bind vial,500,3,7,no,B1,4_D2_1D,TPAD CSF Aliquots Batch3 Box10,B2-B8,2,67,1,Male,Cutpoint #1,103.7,756.3,0.09,669.3,7699,AD,AD,none,none,none,additional sample most likely available,0,34.1,41.1,75.2,E3_E4,67.9,na,FALSE,Cohort 1,November,2019,SSA negative
TPAD0384,1255,HC,0,0,4,A4,vial,2 ml Sarstedt low bind vial,500,2,7,no,H1,4_D1_4C,TPAD CSF Aliquots Batch2 Box9,H2-H8,1,70,1,Male,Cutpoint #1,21.2,110.3,0.13,892.3,7023,HC,none,none,none,none,additional sample most likely available,0,67.3,0,67.3,E3_E3,65.3,E3_E3,TRUE,Cohort 1,December,2019,not completed
TPAD0385,1262,AD,1,0,3A,C7,vial,1.5 ml Eppendorf low bind tube,500,1,8,no,F1,4_D1_2D,TPAD CSF Aliquots Batch1 Box9,F2-F8,2,58,0,Female,Cutpoint #1,127.5,768.3,0.07,639.3,9641,AD,none,none,none,none,additional sample most likely available,0,88.7,0,88.7,E3_E3,93.2,E3_E3,TRUE,Cohort 1,November,2019,SSA negative
TPAD0386,1269,HC,0,0,3A,C4,vial,2 ml Sarstedt low bind vial,500,4,8,no,A1,4_D2_3E,TPAD CSF Aliquots Batch4 Box11,A2-A9,1,54,0,Female,Cutpoint #1,22.4,115.3,0.12,1231.3,10565,HC,none,none,none,none,most likely no additional sample,0,96.6,0,96.6,E3_E3,92.5,E3_E3,TRUE,Cohort 1,February,2020,not completed
TPAD0387,1273,HC,0,0,5,E4,vial,2 ml Sarstedt low bind vial,500,3,7,no,H1,4_D2_1C,TPAD CSF Aliquots Batch3 Box9,H2-H8,1,79,1,Male,Cutpoint #1,61.2,412.3,0.07,762.3,11637,HC,none,none,none,none,additional sample most likely available,0,41,48.3,89.3,E3_E4,81.8,E3_E4,TRUE,Cohort 1,February,2020,not completed
TPAD0388,1279,HC,0,0,1B,E8,vial,2 ml Sarstedt low bind vial,500,4,7,no,I1,4_D2_3D,TPAD CSF Aliquots Batch4 Box10,I2-I8,1,68,0,Female,Cutpoint #1,48.8,282.3,0.06,578.3,9273,HC,none,none,none,none,additional sample most likely available,0,2.3,64.8,67.1,E4_E4,55.4,E4_E4,TRUE,Cohort 1,March,2020,not completed
TPAD0389,101407,AD,1,0,3A,D4,2 ml yellow tube,2 ml Sarstedt low bind vial,1000,4,9,yes,C1,4_D2_1E,TPAD CSF Aliquots Batch4 Box1,C2-D1,2,56,0,Female,Cutpoint #1,189,1190.3,0.07,499.3,7667,none,none,none,none,none,most likely no additional sample,0,0,57.4,57.3,E4_E4,49.3,E4_E4,TRUE,Cohort 4,October,2010,SSA positive
TPAD0390,111188,MCI,1,0,1B,F4,2 ml yellow tube,2 ml Sarstedt low bind vial,1000,4,9,yes,F2,4_D2_1E,TPAD CSF Aliquots Batch4 Box1,F3-G2,2,68,0,Female,Cutpoint #1,89.4,558.3,0.07,647.3,9420,none,none,none,none,none,no additional sample possible,0,1.8,85.3,87.1,E4_E4,86.9,E4_E4,TRUE,Cohort 4,May,2011,not completed
TPAD0391,121059,HC,0,0,5,A2,2 ml yellow tube,2 ml Sarstedt low bind vial,1000,2,9,yes,A9,4_D1_2E,TPAD CSF Aliquots Batch2 Box1,B1-B9,1,68,1,Male,Cutpoint #1,23.5,114.3,0.13,868.3,6787,none,none,none,none,none,no additional sample possible,0,55.3,0,55.3,E3_E3,48.4,E3_E3,TRUE,Cohort 4,February,2012,not completed
TPAD0392,121060,MCI,1,0,3B,F6,2 ml blue tube,2 ml Sarstedt low bind vial,1000,3,9,yes,B1,4_D1_4E,TPAD CSF Aliquots Batch3 Box1,B2-C1,2,73,0,Female,Cutpoint #1,52,377.3,0.11,1281.3,11496,none,none,none,none,none,no additional sample possible,29.3,34.5,0,63.7,E2_E3,59.6,E2_E3,TRUE,Cohort 4,February,2012,SSA negative
TPAD0393,121091,MCI,1,0,3A,D10,2 ml purple tube,2 ml Sarstedt low bind vial,1000,2,9,yes,F2,4_D1_2E,TPAD CSF Aliquots Batch2 Box1,F3-G2,2,75,1,Male,Cutpoint #1,107.9,650.3,0.07,735.3,10689,none,none,none,none,none,no additional sample possible,0,37.6,45.5,83.1,E3_E4,62.7,E3_E4,TRUE,Cohort 4,March,2012,not completed
TPAD0394,121151,MCI,1,0,4,A8,2 ml blue tube,2 ml Sarstedt low bind vial,500,2,9,yes,E1,4_D1_2E,TPAD CSF Aliquots Batch2 Box1,E2-F1,2,64,1,Male,Cutpoint #1,22.8,242.3,0.13,1028.3,8204,none,none,none,none,none,most likely no additional sample,38.1,48,0,86.1,E2_E3,85.6,E2_E3,TRUE,Cohort 4,May,2012,SSA negative
TPAD0395,121235,MCI,na (1),na (0),2A,A10,0.5 ml clear tube,2 ml Sarstedt low bind vial,300,4,4,no,D2,4_D2_1E,TPAD CSF Aliquots Batch4 Box1,D3-D6,2,75,1,Male,Cutpoint #1,63.5,372.3,0.08,584.3,7143,none,none,none,none,none,most likely no additional sample,na,na,na,na,na,na,na,na,Cohort 4,July,2012,SSA negative
TPAD0396,121249,PD-noMCI,na (0),na (1),1B,E12,0.5 ml clear tube,2 ml Sarstedt low bind vial,600,4,3,no,A5,4_D2_2A,TPAD CSF Aliquots Batch4 Box2,A6-A8,3,60.1,1,Male,Cutpoint #2,n/a,203,0.14,831,6014,none,none,none,none,none,no additional sample possible,na,na,na,na,na,na,na,na,Cohort 3,July,2012,SSA positive
TPAD0397,121254,PDD,na (1),na (1),4,B5,0.5 ml clear tube,2 ml Sarstedt low bind vial,600,4,3,no,I5,4_D2_1E,TPAD CSF Aliquots Batch4 Box1,I6-I8,3,67.6,0,Female,Cutpoint #2,n/a,202,0.22,389,1783,none,none,none,none,none,no additional sample possible,na,na,na,na,na,na,na,na,Cohort 3,August,2012,SSA positive
TPAD0398,121257,PD-MCI,na (1),na (1),3B,F12,0.5 ml clear tube,2 ml Sarstedt low bind vial,600,4,3,no,A1,4_D2_2A,TPAD CSF Aliquots Batch4 Box2,A2-A4,3,62.9,0,Female,Cutpoint #1,37.5,246.3,0.12,1160.3,9479,none,none,none,none,none,no additional sample possible,na,na,na,na,na,na,na,na,Cohort 3,August,2012,SSA positive
TPAD0399,121310,PDD,na (1),na (1),2A,D11,0.5 ml clear tube,2 ml Sarstedt low bind vial,400,3,3,no,E2,4_D1_4E,TPAD CSF Aliquots Batch3 Box1,E3-E5,3,74.2,1,Male,Cutpoint #2,66.4,355,0.05,261,5303,none,none,none,none,none,most likely no additional sample,na,na,na,na,na,na,na,na,Cohort 3,September,2012,SSA positive
TPAD0400,121320,PD-noMCI,na (0),na (1),1A,A6,0.5 ml clear tube,2 ml Sarstedt low bind vial,600,4,3,no,A9,4_D2_2A,TPAD CSF Aliquots Batch4 Box2,B1-B3,3,68.8,1,Male,Cutpoint #2,29.2,341,0.12,745,6064,none,none,none,none,none,most likely no additional sample,na,na,na,na,na,na,na,na,Cohort 3,September,2012,SSA positive
TPAD0401,121334,PD-MCI,na (1),na (1),1B,F5,0.5 ml clear tube,2 ml Sarstedt low bind vial,600,2,3,no,I3,4_D1_2E,TPAD CSF Aliquots Batch2 Box1,I4-I6,3,80.1,1,Male,Cutpoint #2,34,333,0.07,312,4704,none,none,none,none,none,additional sample possibly available,na,na,na,na,na,na,na,na,Cohort 3,October,2012,SSA positive
TPAD0402,121338,HC,0,0,5,B10,0.5 ml clear tube,2 ml Sarstedt low bind vial,300,3,9,yes,C2,4_D1_4E,TPAD CSF Aliquots Batch3 Box1,C3-D2,1,69,0,Female,Cutpoint #1,40.2,281.3,0.11,1318.3,12319,none,none,none,none,none,most likely no additional sample,0,93,0,93,E3_E3,85.6,E3_E3,TRUE,Cohort 4,October,2012,not completed
TPAD0403,121347,PD-noMCI,0,1,3B,G11,0.5 ml clear tube,2 ml Sarstedt low bind vial,600,4,9,yes,B2,4_D2_2E,TPAD CSF Aliquots Batch4 Box6,B3-C2,3,80.2,1,Male,Cutpoint #2,30.9,189,0.12,756,6143,none,none,none,none,none,most likely no additional sample,0,60.9,0,60.9,E3_E3,53.3,na,FALSE,Cohort 3,October,2012,SSA positive
TPAD0404,121348,HC,0,0,5,C2,0.5 ml clear tube,2 ml Sarstedt low bind vial,600,3,8,no,F3,4_D1_5C,TPAD CSF Aliquots Batch3 Box4,F4-G2,1,78.1,0,Female,Cutpoint #2,44.7,323,0.11,1036,9143,none,none,none,none,none,additional sample possibly available,37.5,46.5,0,84,E2_E3,80.8,E2_E3,TRUE,Cohort 3,October,2012,SSA negative
TPAD0405,121351,MCI,na (1),na (0),4,B2,0.5 ml clear tube,2 ml Sarstedt low bind vial,300,4,3,no,D7,4_D2_1E,TPAD CSF Aliquots Batch4 Box1,D8-E1,2,72,1,Male,Cutpoint #1,81.5,544.3,0.07,541.3,8226,none,none,none,none,none,additional sample most likely available,na,na,na,na,na,na,na,na,Cohort 4,October,2012,SSA positive
TPAD0406,121356,PD-MCI,1,1,3A,D3,0.5 ml clear tube,2 ml Sarstedt low bind vial,600,3,8,no,C3,4_D1_5C,TPAD CSF Aliquots Batch3 Box4,C4-D2,3,64.7,1,Male,Cutpoint #2,46,1017,0.07,530,7176,none,none,none,none,none,additional sample possibly available,0,120.9,0,120.9,E3_E3,114.6,E3_E3,TRUE,Cohort 3,October,2012,SSA positive
TPAD0407,121370,PD-MCI,1,1,2A,D9,0.5 ml clear tube,2 ml Sarstedt low bind vial,600,3,9,yes,E2,4_D1_5C,TPAD CSF Aliquots Batch3 Box4,E3-F2,3,59.6,0,Female,Cutpoint #2,35.4,302,0.12,1079,9050,none,none,none,none,none,most likely no additional sample,0,47.3,0,47.3,E3_E3,40,E3_E3,TRUE,Cohort 3,October,2012,SSA negative
TPAD0408,121376,DLB,2,2,1B,H10,0.5 ml clear tube,2 ml Sarstedt low bind vial,500,2,8,no,C1,4_D1_2E,TPAD CSF Aliquots Batch2 Box1,C2-C9,3,73,1,Male,Cutpoint #1,57.1,253.3,0.09,426.3,4665,none,none,none,none,none,most likely no additional sample,0,0.5,68.5,69.1,E4_E4,61,na,FALSE,Cohort 4,November,2012,SSA negative
TPAD0409,121390,HC,0,0,5,A10,0.5 ml clear tube,2 ml Sarstedt low bind vial,600,4,8,no,C3,4_D2_2E,TPAD CSF Aliquots Batch4 Box6,C4-D2,1,60.8,0,Female,Cutpoint #2,21.8,127,0.11,423,4004,none,none,none,none,none,additional sample possibly available,0,63.5,0,63.5,E3_E3,55.6,E3_E3,TRUE,Cohort 3,November,2012,not completed
TPAD0410,121411,HC,0,0,5,D2,0.5 ml clear tube,2 ml Sarstedt low bind vial,600,2,9,yes,H3,4_D1_3B,TPAD CSF Aliquots Batch2 Box3,H4-I3,1,74.7,0,Female,Cutpoint #2,63.4,440,0.09,818,8633,none,none,none,none,none,no additional sample possible,0,241.3,0,241.3,E3_E3,205.1,na,FALSE,Cohort 3,December,2012,not completed
TPAD0411,121641,MCI,1,0,2B,E9,2 ml purple tube,2 ml Sarstedt low bind vial,1000,4,9,yes,H4,4_D2_1E,TPAD CSF Aliquots Batch4 Box1,H5-I4,2,72,1,Male,Cutpoint #1,93.4,556.3,0.07,499.3,7391,none,none,none,none,none,no additional sample possible,0,29.5,37.5,66.9,E3_E4,58.9,E3_E4,TRUE,Cohort 4,December,2012,SSA negative
TPAD0412,121652,PD-noMCI,0,1,1B,E6,0.5 ml clear tube,2 ml Sarstedt low bind vial,600,4,8,no,E2,4_D2_1E,TPAD CSF Aliquots Batch4 Box1,E3-F1,3,60.6,1,Male,Cutpoint #2,32.1,163,0.11,534,4670,none,none,none,none,none,additional sample possibly available,0,110.4,0,110.4,E3_E3,105.4,E3_E3,TRUE,Cohort 3,January,2013,SSA positive
TPAD0413,131003,PD-noMCI,0,1,2A,C10,2 ml blue tube,2 ml Sarstedt low bind vial,700,4,8,no,D1,4_D2_2B,TPAD CSF Aliquots Batch4 Box3,D2-D9,3,58.3,1,Male,Cutpoint #2,40,241,0.12,758,6247,none,none,none,none,none,most likely no additional sample,0,93.7,0,93.7,E3_E3,89.3,E3_E3,TRUE,Cohort 3,February,2013,SSA positive
TPAD0414,131013,PD-MCI,1,1,3A,A11,0.5 ml clear tube,2 ml Sarstedt low bind vial,600,2,8,no,D1,4_D1_2E,TPAD CSF Aliquots Batch2 Box1,D2-D9,3,63.3,1,Male,Cutpoint #2,55.7,369,0.12,1305,10831,none,none,none,none,none,most likely no additional sample,0,117,0,117,E3_E3,111,E3_E3,TRUE,Cohort 3,February,2013,SSA positive
TPAD0415,131018,HC,0,0,3A,D5,2 ml yellow tube,2 ml Sarstedt low bind vial,1500,3,9,yes,G2,4_D1_5A,TPAD CSF Aliquots Batch3 Box2,G3-H2,1,63,1,Male,Cutpoint #2,23.7,159,0.1,600,5789,none,none,none,none,none,no additional sample possible,0,70.6,0,70.6,E3_E3,58.2,E3_E3,TRUE,Cohort 3,February,2013,not completed
TPAD0416,131061,HC,0,0,5,A8,2 ml orange tube,2 ml Sarstedt low bind vial,1000,4,9,yes,G3,4_D2_1E,TPAD CSF Aliquots Batch4 Box1,G4-H3,1,77,0,Female,Cutpoint #1,60.7,503.3,0.1,1723.3,16974,none,none,none,none,none,most likely no additional sample,0,151.1,0,151.1,E3_E3,152,E3_E3,TRUE,Cohort 4,April,2013,not completed
TPAD0417,131065,PD-noMCI,0,1,2B,E8,2 ml pink tube,2 ml Sarstedt low bind vial,1500,4,9,yes,D4,4_D2_2D,TPAD CSF Aliquots Batch4 Box5,D5-E4,3,50.4,1,Male,Cutpoint #2,40.3,823,0.14,764,5462,none,none,none,none,none,no additional sample possible,0,91,0,91,E3_E3,88.5,E3_E3,TRUE,Cohort 3,April,2013,SSA positive
TPAD0418,131085,PD-noMCI,0,1,2B,F9,2 ml pink tube,2 ml Sarstedt low bind vial,1500,4,9,yes,H7,4_D2_2C,TPAD CSF Aliquots Batch4 Box4,H8-I7,3,66,0,Female,Cutpoint #2,32.5,587,0.12,629,5084,none,none,none,none,none,no additional sample possible,0,102.6,0,102.6,E3_E3,100.4,E3_E3,TRUE,Cohort 3,April,2013,SSA positive
TPAD0419,131095,MCI,1,0,2B,G10,2 ml purple tube,2 ml Sarstedt low bind vial,1000,2,9,yes,G3,4_D1_2E,TPAD CSF Aliquots Batch2 Box1,G4-H3,2,61,1,Male,Cutpoint #1,36.7,1302.3,0.09,827.3,8925,none,none,none,none,none,no additional sample possible,0,32.1,41.2,73.3,E3_E4,72.7,E3_E4,TRUE,Cohort 4,May,2013,SSA negative
TPAD0420,131112,HC,0,0,5,B9,2 ml blue tube,2 ml Sarstedt low bind vial,1500,3,9,yes,B2,4_D1_5C,TPAD CSF Aliquots Batch3 Box4,B3-C2,1,57.2,1,Male,Cutpoint #2,42.9,297,0.13,1124,8625,none,none,none,none,none,no additional sample possible,0,50.7,65.7,116.4,E3_E4,103.5,E3_E4,TRUE,Cohort 3,May,2013,not completed
TPAD0421,131113,PD-noMCI,0,1,3A,C12,2 ml yellow tube,2 ml Sarstedt low bind vial,1500,4,9,yes,C3,4_D2_2D,TPAD CSF Aliquots Batch4 Box5,C4-D3,3,57.9,0,Female,Cutpoint #2,21.4,139,0.11,334,3026,none,none,none,none,none,no additional sample possible,0,18.3,21.1,39.4,E3_E4,33.1,E3_E4,TRUE,Cohort 3,May,2013,SSA positive
TPAD0422,131134,MCI,1,0,1A,A12,2 ml orange tube,2 ml Sarstedt low bind vial,500,2,7,no,H4,4_D1_2E,TPAD CSF Aliquots Batch2 Box1,H5-I2,2,66,1,Male,Cutpoint #1,73.3,463.3,0.07,600.3,9193,none,none,none,none,none,most likely no additional sample,0,37.8,48.2,86.1,E3_E4,81,E3_E4,TRUE,Cohort 4,June,2013,SSA negative
TPAD0423,131135,HC,0,0,2B,G9,2 ml purple tube,2 ml Sarstedt low bind vial,1500,4,9,yes,E1,4_D2_2B,TPAD CSF Aliquots Batch4 Box3,E2-F1,1,56.9,1,Male,Cutpoint #2,27.9,158,0.11,741,6479,none,none,none,none,none,no additional sample possible,0,79.8,0,79.8,E3_E3,76.8,E3_E3,TRUE,Cohort 3,June,2013,not completed
TPAD0424,131137,PD-noMCI,0,1,1B,F1,2 ml blue tube,2 ml Sarstedt low bind vial,1500,4,9,yes,F2,4_D2_2B,TPAD CSF Aliquots Batch4 Box3,F3-G2,3,51.5,0,Female,Cutpoint #2,30.3,205,0.11,855,7770,none,none,none,none,none,no additional sample possible,0,100.8,0,100.8,E3_E3,97.6,E3_E3,TRUE,Cohort 3,June,2013,SSA positive
TPAD0425,131141,HC,0,0,3A,A12,2 ml green tube,2 ml Sarstedt low bind vial,1500,3,9,yes,H3,4_D1_5A,TPAD CSF Aliquots Batch3 Box2,H4-I3,1,56.7,1,Male,Cutpoint #2,28.4,169,0.09,449,5240,none,none,none,none,none,no additional sample possible,0,33.5,39.7,73.3,E3_E4,69.5,na,FALSE,Cohort 3,June,2013,not completed
TPAD0426,131183,PD-noMCI,0,1,3A,D7,2 ml orange tube,2 ml Sarstedt low bind vial,1500,3,9,yes,B2,4_D1_5B,TPAD CSF Aliquots Batch3 Box3,B3-C2,3,65.4,1,Male,Cutpoint #2,26.3,229,0.11,559,5000,none,none,none,none,none,no additional sample possible,0,99.9,0,99.9,E3_E3,91.9,E3_E3,TRUE,Cohort 3,July,2013,SSA positive
TPAD0427,131190,PD-MCI,1,1,4,C4,2 ml blue tube,2 ml Sarstedt low bind vial,1500,4,9,yes,G3,4_D2_2B,TPAD CSF Aliquots Batch4 Box3,G4-H3,3,64,1,Male,Cutpoint #2,41.2,343,0.12,760,6294,none,none,none,none,none,no additional sample possible,0,97.8,0,97.8,E3_E3,92.5,E3_E3,TRUE,Cohort 3,July,2013,SSA positive
TPAD0428,131201,PD-noMCI,0,1,1A,C8,2 ml pink tube,2 ml Sarstedt low bind vial,1500,3,9,yes,A1,4_D1_5B,TPAD CSF Aliquots Batch3 Box3,A2-B1,3,61.4,1,Male,Cutpoint #2,38.6,275,0.14,832,5834,none,none,none,none,none,no additional sample possible,44.5,55.9,0,100.5,E2_E3,92.8,E2_E3,TRUE,Cohort 3,July,2013,SSA negative
TPAD0429,131242,HC,0,0,2B,G6,2 ml pink tube,2 ml Sarstedt low bind vial,1500,3,9,yes,F1,4_D1_5A,TPAD CSF Aliquots Batch3 Box2,F1-G1,1,75.8,0,Female,Cutpoint #2,22.4,142,0.06,282,4417,none,none,none,none,none,no additional sample possible,0,0,83.9,83.6,E4_E4,72.3,E4_E4,TRUE,Cohort 3,August,2013,not completed
TPAD0430,131276,HC,0,0,3A,D12,2 ml orange tube,1.5 ml Eppendorf low bind tube,500,1,8,yes,E1,4_D1_1D,TPAD CSF Aliquots Batch1 Box4,E2-E8,1,81,1,Male,Cutpoint #1,45.5,323.8,0.1,1175.3,11316.9,none,none,none,none,Added meta,additional sample most likely available,0,45.8,49.5,95.3,E3_E4,85.5,E3_E4,TRUE,Cohort 2,November,2014,not completed
TPAD0431,131286,PD-MCI,1,1,4,A3,2 ml blue tube,2 ml Sarstedt low bind vial,1500,2,9,yes,F1,4_D1_3B,TPAD CSF Aliquots Batch2 Box3,F2-G1,3,65.8,0,Female,Cutpoint #2,41.9,293,0.09,642,7398,none,none,none,none,none,no additional sample possible,0,76.8,0,76.8,E3_E3,74.1,E3_E3,TRUE,Cohort 3,September,2013,SSA positive
TPAD0432,131291,HC,0,0,4,A5,2 ml orange tube,2 ml Sarstedt low bind vial,1500,4,9,yes,H8,4_D2_2D,TPAD CSF Aliquots Batch4 Box5,H9-I8,1,57.8,0,Female,Cutpoint #2,20.3,116,0.13,519,4091,none,none,none,none,none,most likely no additional sample,0,65,0,65,E3_E3,58,E3_E3,TRUE,Cohort 3,September,2013,not completed
TPAD0433,131326,PD-noMCI,0,1,4,C9,2 ml purple tube,2 ml Sarstedt low bind vial,1500,4,9,yes,A1,4_D2_2D,TPAD CSF Aliquots Batch4 Box5,A2-B1,3,72.2,0,Female,Cutpoint #2,30.4,198,0.1,512,4968,none,none,none,none,none,no additional sample possible,0,34.3,39.6,73.9,E3_E4,68,E3_E4,TRUE,Cohort 3,October,2013,SSA positive
TPAD0434,131327,PD-noMCI,0,1,1A,D11,2 ml pink tube,2 ml Sarstedt low bind vial,1500,4,9,yes,A1,4_D2_2E,TPAD CSF Aliquots Batch4 Box6,A2-B1,3,69.9,1,Male,Cutpoint #2,35.7,230,0.12,793,6346,none,none,none,none,none,no additional sample possible,0,92.1,0,92.1,E3_E3,91.8,E3_E3,TRUE,Cohort 3,October,2013,SSA positive
TPAD0435,131351,PD-MCI,1,1,3B,E9,2 ml pink tube,2 ml Sarstedt low bind vial,1500,2,9,yes,G2,4_D1_3B,TPAD CSF Aliquots Batch2 Box3,G3-H2,3,70.6,0,Female,Cutpoint #2,32.5,342,0.11,475,4252,none,none,none,none,none,additional sample possibly available,0,91.1,0,91.1,E3_E3,92.4,E3_E3,TRUE,Cohort 3,October,2013,SSA positive
TPAD0436,131379,PDD,1,1,2A,A1,2 ml clear tube,2 ml Sarstedt low bind vial,1500,2,9,yes,E1,4_D1_3A,TPAD CSF Aliquots Batch2 Box2,E2-F1,3,78.3,1,Male,Cutpoint #2,41.6,268,0.11,862,7961,none,none,none,none,none,no additional sample possible,0,104.7,0,104.7,E3_E3,111.9,E3_E3,TRUE,Cohort 3,November,2013,SSA positive
TPAD0437,131387,PDD,1,1,1B,H3,2 ml clear tube,2 ml Sarstedt low bind vial,1500,2,9,yes,F2,4_D1_3A,TPAD CSF Aliquots Batch2 Box2,F3-G2,3,78.7,1,Male,Cutpoint #2,155.5,851,0.06,644,10336,none,none,none,none,none,no additional sample possible,0,111.4,0,111.4,E3_E3,111,E3_E3,TRUE,Cohort 3,November,2013,SSA positive
TPAD0438,131432,MCI,1,0,3B,H1,2 ml clear tube,2 ml Sarstedt low bind vial,500,3,8,no,F7,4_D1_4E,TPAD CSF Aliquots Batch3 Box1,F8-G6,2,73,1,Male,Cutpoint #1,73.8,488.3,0.07,701.3,9997,none,none,none,none,none,additional sample possibly available,0,52.5,64.5,117.1,E3_E4,115.6,E3_E4,TRUE,Cohort 4,December,2013,SSA negative
TPAD0439,131447,PD-noMCI,0,1,2A,B8,2 ml clear tube,2 ml Sarstedt low bind vial,1500,3,9,yes,D9,4_D1_5A,TPAD CSF Aliquots Batch3 Box2,E1-E9,3,71.3,1,Male,Cutpoint #2,31.7,195,0.14,1141,8130,none,none,none,none,none,no additional sample possible,0,55.9,63.2,119.1,E3_E4,110.2,E3_E4,TRUE,Cohort 3,December,2013,SSA positive
TPAD0440,141002,MCI,1,0,3A,A5,2 ml clear tube,2 ml Sarstedt low bind vial,500,3,8,no,G7,4_D1_4E,TPAD CSF Aliquots Batch3 Box1,G8-H6,2,82,1,Male,Cutpoint #1,127.9,689.3,0.05,600.3,11278,none,none,none,none,none,most likely no additional sample,0,77.9,0,77.9,E3_E3,77.3,E3_E3,TRUE,Cohort 4,January,2014,SSA negative
TPAD0441,141006,MCI,1,0,2B,G12,2 ml clear tube,2 ml Sarstedt low bind vial,500,2,8,no,C1,4_D1_3A,TPAD CSF Aliquots Batch2 Box2,C2-C9,2,76,0,Female,Cutpoint #1,124,793.3,0.07,559.3,8227,none,none,none,none,none,most likely no additional sample,0,39.3,41.5,80.9,E3_E4,75,E3_E4,TRUE,Cohort 4,January,2014,SSA negative
TPAD0442,141019,MCI,1,0,1B,E3,2 ml clear tube,2 ml Sarstedt low bind vial,500,3,8,no,H7,4_D1_4E,TPAD CSF Aliquots Batch3 Box1,H8-I6,2,72,1,Male,Cutpoint #1,108.7,627.3,0.07,620.3,8434,none,none,none,none,none,most likely no additional sample,0,35.4,52.5,88,E3_E4,75.4,E3_E4,TRUE,Cohort 4,January,2014,SSA negative
TPAD0443,141041,AD,1,0,2A,C8,2 ml clear tube,2 ml Sarstedt low bind vial,500,4,8,no,D4,4_D2_2A,TPAD CSF Aliquots Batch4 Box2,D5-E3,2,65,0,Female,Cutpoint #1,48.1,279.3,0.1,601.3,6134,none,none,none,none,none,additional sample possibly available,0,28,31.1,59.1,E3_E4,57.8,na,FALSE,Cohort 4,December,2014,SSA negative
TPAD0444,141064,MCI,1,0,4,D6,2 ml clear tube,2 ml Sarstedt low bind vial,500,3,8,no,A1,4_D1_5A,TPAD CSF Aliquots Batch3 Box2,A2-A9,2,68,1,Male,Cutpoint #1,254.4,1592.3,0.05,623.3,11709,none,none,none,none,none,most likely no additional sample,0,63.2,74.8,138.1,E3_E4,138.3,E3_E4,TRUE,Cohort 4,February,2014,SSA negative
TPAD0445,141070,PD-MCI,1,1,2B,F5,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,8,no,E1,4_D1_1B,TPAD CSF Aliquots Batch1 Box2,E2-E8,3,73.7,1,Male,Cutpoint #2,48.3,325,0.08,490,6139,none,none,none,none,none,additional sample most likely available,0,89.4,0,89.4,E3_E3,79.6,E3_E3,TRUE,Cohort 3,February,2014,SSA positive
TPAD0446,141074,PD-MCI,1,1,2B,E6,2 ml clear tube,2 ml Sarstedt low bind vial,700,3,8,no,C9,4_D1_5A,TPAD CSF Aliquots Batch3 Box2,D1-D8,3,80,1,Male,Cutpoint #2,58.8,374,0.07,524,7286,none,none,none,none,none,additional sample most likely available,46.3,58.2,0,104.5,E2_E3,104.5,E2_E3,TRUE,Cohort 3,February,2014,SSA positive
TPAD0447,141078,HC,0,0,5,B8,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,7,no,C1,4_D1_1A,TPAD CSF Aliquots Batch1 Box1,C2-C7,1,65.9,0,Female,Cutpoint #2,18.8,114,0.13,525,4089,none,none,none,none,none,additional sample most likely available,0,28,28.5,56.5,E3_E4,49.4,E3_E4,TRUE,Cohort 3,February,2014,not completed
TPAD0448,141085,AD,1,0,1A,D10,2 ml clear tube,2 ml Sarstedt low bind vial,500,2,8,no,B1,4_D1_3A,TPAD CSF Aliquots Batch2 Box2,B2-B9,2,67,0,Female,Cutpoint #1,72.9,386.3,0.07,683.3,9346,none,none,none,none,none,most likely no additional sample,0,29.7,42.6,72.3,E3_E4,70.2,na,FALSE,Cohort 4,February,2014,SSA negative
TPAD0449,141088,PD-MCI,1,1,2B,H2,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,8,no,H1,4_D1_1A,TPAD CSF Aliquots Batch1 Box1,H2-H8,3,68,0,Female,Cutpoint #2,26.1,236,0.15,876,6017,none,none,none,none,none,additional sample most likely available,22.7,33.5,0,56.2,E2_E3,57.7,E2_E3,TRUE,Cohort 3,March,2014,SSA positive
TPAD0450,141091,HC,0,0,1B,H7,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,8,no,G1,4_D1_1A,TPAD CSF Aliquots Batch1 Box1,G2-G8,1,75,1,Male,Cutpoint #2,30.2,178,0.12,959,7815,none,none,none,none,none,additional sample most likely available,0,93.9,0,93.9,E3_E3,90.2,E3_E3,TRUE,Cohort 3,March,2014,SSA negative
TPAD0451,141099,PD-noMCI,0,1,3A,B6,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,8,no,G1,4_D1_1B,TPAD CSF Aliquots Batch1 Box2,G2-G8,3,67.4,1,Male,Cutpoint #2,62.3,363,0.05,603,11146,none,none,none,none,none,additional sample most likely available,0,131.6,0,131.6,E3_E3,118.6,E3_E3,TRUE,Cohort 3,March,2014,SSA positive
TPAD0452,141112,PD-MCI,1,1,3B,E7,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,8,no,H1,4_D1_1B,TPAD CSF Aliquots Batch1 Box2,H2-H8,3,65.8,1,Male,Cutpoint #2,16.4,93,0.11,564,4948,none,none,none,none,none,additional sample most likely available,0,22.3,26.3,48.6,E3_E4,51.7,E3_E4,TRUE,Cohort 3,March,2014,SSA positive
TPAD0453,141124,MCI,1,0,3B,H12,2 ml clear tube,2 ml Sarstedt low bind vial,500,4,8,no,G4,4_D2_2A,TPAD CSF Aliquots Batch4 Box2,G5-H3,2,73,1,Male,Cutpoint #1,121.5,779.3,0.05,772.3,15472,none,none,none,none,none,additional sample possibly available,0,64.4,80.2,144.6,E3_E4,140.2,na,FALSE,Cohort 4,March,2014,SSA positive
TPAD0454,141130,PD-noMCI,0,1,4,D3,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,8,no,I1,4_D1_1B,TPAD CSF Aliquots Batch1 Box2,I2-I8,3,73.5,1,Male,Cutpoint #2,26.4,165,0.14,1072,7827,none,none,none,none,none,additional sample most likely available,0,61.8,0,61.8,E3_E3,55.5,E3_E3,TRUE,Cohort 3,March,2014,SSA negative
TPAD0455,141132,PDD,1,1,4,D11,2 ml clear tube,2 ml Sarstedt low bind vial,700,2,9,yes,G3,4_D1_3A,TPAD CSF Aliquots Batch2 Box2,G4-H3,3,83.5,0,Female,Cutpoint #2,72.2,464,0.05,515,9513,none,none,none,none,none,additional sample possibly available,0,117.7,0,117.7,E3_E3,102.5,E3_E3,TRUE,Cohort 3,March,2014,SSA positive
TPAD0456,141162,PD-MCI,1,1,3B,G2,2 ml clear tube,2 ml Sarstedt low bind vial,1500,3,9,yes,A1,4_D1_5C,TPAD CSF Aliquots Batch3 Box4,A2-B1,3,67.5,1,Male,Cutpoint #2,29.3,1220,0.13,1075,8264,none,none,none,none,none,additional sample possibly available,0,66.6,0,66.6,E3_E3,59.7,E3_E3,TRUE,Cohort 3,April,2014,SSA positive
TPAD0457,141164,HC,0,0,3B,G4,2 ml clear tube,2 ml Sarstedt low bind vial,500,4,8,no,F4,4_D2_2A,TPAD CSF Aliquots Batch4 Box2,F5-G3,1,62,1,Male,Cutpoint #1,37.8,222.3,0.12,1222.3,10505,none,none,none,none,none,additional sample possibly available,0,91.8,0,91.8,E3_E3,88.8,na,FALSE,Cohort 4,April,2014,SSA negative
TPAD0458,141168,AD,1,0,1A,C3,2 ml clear tube,2 ml Sarstedt low bind vial,500,4,8,no,E4,4_D2_2A,TPAD CSF Aliquots Batch4 Box2,E5-F3,2,68,1,Male,Cutpoint #1,25.2,169.3,0.12,1020.3,8795,none,none,none,none,none,additional sample possibly available,33,40.3,0,73.3,E2_E3,69.7,na,FALSE,Cohort 4,April,2014,SSA negative
TPAD0459,141171,AD,1,0,3B,G9,2 ml clear tube,1.5 ml Eppendorf low bind tube,500,1,7,no,B1,4_D1_1A,TPAD CSF Aliquots Batch1 Box1,B2-B7,2,68,0,Female,Cutpoint #1,70.3,532.3,0.09,613.3,7185,none,none,none,none,none,additional sample most likely available,0,73.1,0,73.1,E3_E3,65.6,na,FALSE,Cohort 4,April,2014,SSA negative
TPAD0460,141175,PDD,1,1,3A,A1,2 ml clear tube,2 ml Sarstedt low bind vial,700,4,9,no,F6,4_D2_2D,TPAD CSF Aliquots Batch4 Box5,F7-G6,3,64.2,1,Male,Cutpoint #2,19.3,116,0.12,493,4104,none,none,none,none,none,no additional sample possible,0,73.9,0,73.9,E3_E3,62.3,E3_E3,TRUE,Cohort 3,April,2014,SSA positive
TPAD0461,141177,PD-noMCI,0,1,1A,C2,2 ml clear tube,2 ml Sarstedt low bind vial,1500,4,9,yes,E5,4_D2_2D,TPAD CSF Aliquots Batch4 Box5,E6-F5,3,63.1,0,Female,Cutpoint #2,17.8,136,0.13,515,4106,none,none,none,none,none,most likely no additional sample,0,40.2,0,40.2,E3_E3,35.8,E3_E3,TRUE,Cohort 3,April,2014,not completed
TPAD0462,141179,PD-noMCI,0,1,2B,H5,2 ml clear tube,2 ml Sarstedt low bind vial,1500,4,9,yes,G7,4_D2_2D,TPAD CSF Aliquots Batch4 Box5,G8-H7,3,56.8,0,Female,Cutpoint #2,24.1,153,0.12,946,7699,none,none,none,none,none,additional sample possibly available,0,95.3,0,95.3,E3_E3,83.8,E3_E3,TRUE,Cohort 3,April,2014,SSA positive
TPAD0463,141180,PD-MCI,1,1,1A,D4,2 ml clear tube,2 ml Sarstedt low bind vial,1500,4,9,yes,B2,4_D2_2D,TPAD CSF Aliquots Batch4 Box5,B3-C2,3,70.3,0,Female,Cutpoint #2,62.1,1267,0.08,748,9646,none,none,none,none,none,additional sample possibly available,0,129.8,0,129.8,E3_E3,123.6,E3_E3,TRUE,Cohort 3,April,2014,SSA positive
TPAD0464,141198,HC,0,0,3B,E2,2 ml clear tube,2 ml Sarstedt low bind vial,500,3,8,no,B1,4_D1_5A,TPAD CSF Aliquots Batch3 Box2,B2-B9,1,82,1,Male,Cutpoint #1,49.1,387.3,0.12,1512.3,12948,none,none,none,none,none,additional sample most likely available,60.2,78.7,0,139,E2_E3,138.1,na,FALSE,Cohort 4,May,2014,SSA positive
TPAD0465,141201,PD-MCI,1,1,3A,C5,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,8,no,G1,4_D1_1D,TPAD CSF Aliquots Batch1 Box4,G2-G8,3,85.8,1,Male,Cutpoint #2,158,993,0.06,879,15201,none,none,none,none,none,additional sample most likely available,84.8,97.8,0,182.6,E2_E3,166.9,E2_E3,TRUE,Cohort 3,May,2014,SSA negative
TPAD0466,141202,PDD,1,1,2B,E12,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,8,no,F1,4_D1_1D,TPAD CSF Aliquots Batch1 Box4,F2-F8,3,69.3,0,Female,Cutpoint #2,80.1,525,0.08,503,6262,none,none,none,none,none,additional sample most likely available,0,75.1,0,75.1,E3_E3,74.5,E3_E3,TRUE,Cohort 3,May,2014,SSA positive
TPAD0467,141210,HC,0,0,1A,A8,2 ml clear tube,2 ml Sarstedt low bind vial,500,4,8,no,H4,4_D2_2A,TPAD CSF Aliquots Batch4 Box2,H5-I3,1,76,1,Male,Cutpoint #1,33.6,298.3,0.11,1133.3,10421,none,none,none,none,none,additional sample most likely available,36.1,0,49.8,85.1,E2_E4,71.6,na,FALSE,Cohort 4,May,2014,SSA negative
TPAD0468,141214,MCI,1,0,3A,C3,2 ml clear tube,2 ml Sarstedt low bind vial,500,2,8,no,D1,4_D1_3A,TPAD CSF Aliquots Batch2 Box2,D2-D9,2,64,0,Female,Cutpoint #1,82.8,452.3,0.07,654.3,9552,none,none,none,none,none,additional sample most likely available,0,29.3,39.4,68.7,E3_E4,65.7,na,FALSE,Cohort 4,May,2014,SSA negative
TPAD0469,141217,PD-MCI,1,1,1B,G9,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,8,no,E1,4_D1_1E,TPAD CSF Aliquots Batch1 Box5,E2-E8,3,71,1,Male,Cutpoint #2,36.6,233,0.13,1099,8432,none,none,none,none,none,additional sample most likely available,0,89,0,89,E3_E3,78.4,E3_E3,TRUE,Cohort 3,May,2014,SSA positive
TPAD0470,141222,HC,0,0,1A,C9,2 ml clear tube,2 ml Sarstedt low bind vial,500,4,8,no,A1,4_D2_2B,TPAD CSF Aliquots Batch4 Box3,A2-A9,1,84,1,Male,Cutpoint #1,40.8,388.3,0.1,1318.3,12624,none,none,none,none,none,additional sample most likely available,0,101,0,101,E3_E3,103.9,na,FALSE,Cohort 4,May,2014,SSA negative
TPAD0471,141229,HC,0,0,5,D5,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,7,no,C1,4_D1_1E,TPAD CSF Aliquots Batch1 Box5,C2-C8,1,59.7,1,Male,Cutpoint #2,26.8,181,0.13,921,7113,none,none,none,none,none,additional sample most likely available,41.7,52.9,0,94.6,E2_E3,82.2,E2_E3,TRUE,Cohort 3,June,2014,not completed
TPAD0472,141232,HC,0,0,4,A2,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,8,no,A1,4_D1_1C,TPAD CSF Aliquots Batch1 Box3,A2-A7,1,70.6,0,Female,Cutpoint #2,48.6,294,0.06,613,9780,none,none,none,none,none,additional sample most likely available,0,48,49.2,97.2,E3_E4,99.9,E3_E4,TRUE,Cohort 3,June,2014,not completed
TPAD0473,141236,HC,0,0,5,B11,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,8,no,F1,4_D1_1B,TPAD CSF Aliquots Batch1 Box2,F2-F8,1,62.3,1,Male,Cutpoint #2,43.1,310,0.12,1476,11873,none,none,none,none,none,additional sample most likely available,0,115.1,0,115.1,E3_E3,104.7,E3_E3,TRUE,Cohort 3,June,2014,SSA negative
TPAD0474,141262,HC,0,0,4,D10,2 ml clear tube,2 ml Sarstedt low bind vial,500,3,7,no,C1,4_D1_5A,TPAD CSF Aliquots Batch3 Box2,C2-C8,1,55,0,Female,Cutpoint #1,30,177.3,0.09,976.3,10784,none,none,none,none,none,additional sample most likely available,38.4,50.8,0,89.3,E2_E3,84.7,na,FALSE,Cohort 4,July,2014,SSA negative
TPAD0475,141268,HC,0,0,5,E12,2 ml clear tube,2 ml Sarstedt low bind vial,500,4,8,no,C2,4_D2_3E,TPAD CSF Aliquots Batch4 Box11,C3-D1,1,71,0,Female,Cutpoint #1,56.3,444.8,0.08,1044.3,12773.9,none,none,none,none,none,additional sample possibly available,46.1,1.3,60.7,108.1,E2_E4,100.4,E2_E4,TRUE,Cohort 2,July,2014,not completed
TPAD0476,141295,HC,0,0,4,B10,2 ml clear tube,2 ml Sarstedt low bind vial,500,4,7,no,B1,4_D2_2B,TPAD CSF Aliquots Batch4 Box3,B2-B8,1,58,0,Female,Cutpoint #1,24.5,122.3,0.11,1137.3,10526,none,none,none,none,none,additional sample most likely available,38,44.8,0,82.8,E2_E3,84.1,na,FALSE,Cohort 4,August,2014,SSA negative
TPAD0477,141304,HC,0,0,3B,H11,2 ml clear tube,2 ml Sarstedt low bind vial,500,2,7,no,A1,4_D1_2E,TPAD CSF Aliquots Batch2 Box1,A2-A8,1,79,0,Female,Cutpoint #1,21.3,122.3,0.13,930.3,7411,none,none,none,none,none,additional sample most likely available,31.2,44.7,0,75.9,E2_E3,78.4,na,FALSE,Cohort 4,August,2014,SSA negative
TPAD0478,141308,PD-MCI,1,1,2A,B12,0.5 ml clear tube,2 ml Sarstedt low bind vial,600,3,7,no,D3,4_D1_4E,TPAD CSF Aliquots Batch3 Box1,D4-E1,3,78.4,1,Male,Cutpoint #2,44.1,252,0.08,477,5799,none,none,none,none,none,additional sample most likely available,0,89.1,0,89.1,E3_E3,82.1,E3_E3,TRUE,Cohort 3,August,2014,SSA positive
TPAD0479,141312,PD-noMCI,0,1,2B,G7,2 ml clear tube,2 ml Sarstedt low bind vial,1500,4,9,yes,B9,4_D2_2B,TPAD CSF Aliquots Batch4 Box3,C1-C9,3,73.4,0,Female,Cutpoint #2,34.9,249,0.14,1193,8566,none,none,none,none,none,most likely no additional sample,0,33.6,39.9,73.5,E3_E4,64,E3_E4,TRUE,Cohort 3,August,2014,SSA positive
TPAD0480,141318,PD-MCI,1,1,2B,G1,2 ml clear tube,1.5 ml Eppendorf low bind tube,600,1,8,no,D1,4_D1_1E,TPAD CSF Aliquots Batch1 Box5,D2-D8,3,76,1,Male,Cutpoint #2,55.7,345,0.06,383,6092,none,none,none,none,none,additional sample most likely available,0,46.6,50,96.6,E3_E4,89.3,E3_E4,TRUE,Cohort 3,August,2014,SSA positive
TPAD0481,141327,PD-MCI,1,1,3B,F10,0.5 ml clear tube,2 ml Sarstedt low bind vial,600,3,7,no,D3,4_D1_5C,TPAD CSF Aliquots Batch3 Box4,D4-E1,3,79.7,1,Male,Cutpoint #2,43.2,291,0.13,1682,12737,none,none,none,none,none,additional sample most likely available,0,115.8,0,115.8,E3_E3,111.7,E3_E3,TRUE,Cohort 3,August,2014,SSA positive
TPAD0482,141335,PDD,1,1,1A,A3,0.5 ml clear tube,1.5 ml Eppendorf low bind tube,600,1,8,no,A1,4_D1_1A,TPAD CSF Aliquots Batch1 Box1,A2-A8,3,64.7,1,Male,Cutpoint #2,31.2,178,0.08,345,4191,none,none,none,none,none,additional sample most likely available,0,24.3,29.7,54.1,E3_E4,46.3,E3_E4,TRUE,Cohort 3,September,2014,SSA positive
TPAD0483,141336,PD-MCI,1,1,1B,H6,0.5 ml clear tube,2 ml Sarstedt low bind vial,600,3,8,no,G3,4_D1_5C,TPAD CSF Aliquots Batch3 Box4,G4-H2,3,69.2,1,Male,Cutpoint #2,35.6,285,0.1,576,5656,none,none,none,none,none,additional sample most likely available,0,38.9,41.9,80.9,E3_E4,77.2,E3_E4,TRUE,Cohort 3,September,2014,SSA positive
TPAD0484,141337,HC,0,0,3A,D11,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,7,no,E1,4_D1_1A,TPAD CSF Aliquots Batch1 Box1,E2-E7,1,69.5,0,Female,Cutpoint #2,52.6,359,0.12,1478,11910,none,none,none,none,none,additional sample most likely available,0,112.1,0,112.1,E3_E3,109.8,E3_E3,TRUE,Cohort 3,September,2014,SSA negative
TPAD0485,141345,HC,0,0,3B,F4,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,10,no,D1,4_D1_1A,TPAD CSF Aliquots Batch1 Box1,"D2-D9, E9",1,79.3,0,Female,Cutpoint #2,27.4,169,0.13,806,6188,none,none,none,none,none,additional sample most likely available,0,31.1,37,68.1,E3_E4,56.9,E3_E4,TRUE,Cohort 3,September,2014,not completed
TPAD0486,141346,HC,0,0,4,B12,2 ml clear tube,1.5 ml Eppendorf low bind tube,600,1,8,no,F1,4_D1_1A,TPAD CSF Aliquots Batch1 Box1,F2-F8,1,64.8,1,Male,Cutpoint #2,46.7,343,0.15,1658,11275,none,none,none,none,none,additional sample most likely available,52.9,69.4,0,122.3,E2_E3,112.5,E2_E3,TRUE,Cohort 3,September,2014,SSA negative
TPAD0487,141348,MCI,1,0,1A,C6,2 ml clear tube,1.5 ml Eppendorf low bind tube,500,1,8,no,B1,4_D1_1C,TPAD CSF Aliquots Batch1 Box3,B2-B8,2,75,0,Female,Cutpoint #1,139.2,975.8,0.05,864.3,16860.9,none,none,none,none,Added meta,additional sample most likely available,0,71.3,74.1,145.4,E3_E4,137.4,na,FALSE,Cohort 2,September,2014,not completed
TPAD0488,141352,PD-noMCI,0,1,2A,B6,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,8,no,D1,4_D1_1B,TPAD CSF Aliquots Batch1 Box2,D2-D8,3,58.4,0,Female,Cutpoint #2,26.8,178,0.1,592,5958,none,none,none,none,none,additional sample most likely available,0,70.7,0,70.7,E3_E3,62.6,E3_E3,TRUE,Cohort 3,September,2014,SSA positive
TPAD0489,141353,HC,0,0,1A,C7,2 ml clear tube,1.5 ml Eppendorf low bind tube,500,1,8,no,C1,4_D1_1C,TPAD CSF Aliquots Batch1 Box3,C2-C8,1,81,0,Female,Cutpoint #1,49.4,360.8,0.1,1169.3,11338.9,none,none,none,none,Added meta,additional sample most likely available,0,118.7,0,118.7,E3_E3,123.2,E3_E3,TRUE,Cohort 2,November,2014,not completed
TPAD0490,141361,HC,0,0,2A,C2,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,8,no,B1,4_D1_1B,TPAD CSF Aliquots Batch1 Box2,B2-B8,1,65.2,0,Female,Cutpoint #2,30.6,196,0.12,961,7836,none,none,none,none,none,additional sample most likely available,0,82.6,0,82.6,E3_E3,72.1,E3_E3,TRUE,Cohort 3,September,2014,SSA negative
TPAD0491,141362,HC,0,0,2A,A9,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,8,no,C1,4_D1_1B,TPAD CSF Aliquots Batch1 Box2,C2-C8,1,62,0,Female,Cutpoint #2,36.5,269,0.13,1292,9874,none,none,none,none,none,additional sample most likely available,40.2,49.9,0,90.1,E2_E3,94.9,E2_E3,TRUE,Cohort 3,September,2014,SSA negative
TPAD0492,141364,HC,0,0,5,D6,2 ml clear tube,1.5 ml Eppendorf low bind tube,500,1,8,no,H1,4_D1_1C,TPAD CSF Aliquots Batch1 Box3,H2-H8,1,74,0,Female,Cutpoint #1,47.6,360.8,0.12,1259.3,10791.9,none,none,none,none,Added meta,additional sample most likely available,0,86.4,0,86.4,E3_E3,76.4,E3_E3,TRUE,Cohort 2,September,2014,not completed
TPAD0493,141365,PDD,1,1,3B,F3,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,8,no,B1,4_D1_1E,TPAD CSF Aliquots Batch1 Box5,B2-B8,3,72.5,1,Male,Cutpoint #2,35.8,207,0.07,296,4392,none,none,none,none,none,additional sample most likely available,34.9,46.5,0,81.4,E2_E3,72.1,E2_E3,TRUE,Cohort 3,September,2014,SSA positive
TPAD0494,141370,HC,0,0,5,B12,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,8,no,I1,4_D1_1A,TPAD CSF Aliquots Batch1 Box1,I2-I8,1,64.9,0,Female,Cutpoint #2,49.8,373,0.12,1619,12954,none,none,none,none,none,additional sample most likely available,0,125.4,0,125.4,E3_E3,116.3,E3_E3,TRUE,Cohort 3,October,2014,SSA positive
TPAD0495,141372,PD-noMCI,0,1,2B,H12,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,8,no,A1,4_D1_1B,TPAD CSF Aliquots Batch1 Box2,A2-A8,3,62.5,0,Female,Cutpoint #2,19,100,0.12,526,4300,none,none,none,none,none,additional sample most likely available,22.8,33,0,55.8,E2_E3,49.2,E2_E3,TRUE,Cohort 3,October,2014,SSA positive
TPAD0496,141374,PD-noMCI,0,1,2B,F2,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,8,no,I1,4_D1_1D,TPAD CSF Aliquots Batch1 Box4,I2-I7,3,73.3,0,Female,Cutpoint #2,33.8,207,0.09,899,9769,none,none,none,none,none,additional sample most likely available,88.5,4,0,92.5,E2_E2,84,na,FALSE,Cohort 3,October,2014,SSA positive
TPAD0497,141387,HC,0,0,1A,B6,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,8,no,A1,4_D1_1E,TPAD CSF Aliquots Batch1 Box5,A2-A8,1,65.6,0,Female,Cutpoint #2,23.5,169,0.14,909,6731,none,none,none,none,none,additional sample most likely available,60.6,0.4,0,61,E2_E2,60,E2_E2,TRUE,Cohort 3,October,2014,not completed
TPAD0498,141433,HC,0,0,1B,E11,2 ml clear tube,2 ml Sarstedt low bind vial,500,3,8,no,A1,4_D1_4E,TPAD CSF Aliquots Batch3 Box1,A2-A9,1,71,1,Male,Cutpoint #1,28.2,178.3,0.11,835.3,7745,none,none,none,none,none,additional sample most likely available,0,71.4,0,71.4,E3_E3,69.2,E3_E3,TRUE,Cohort 4,December,2014,not completed
TPAD0499,141435,HC,0,0,1A,D2,2 ml clear tube,2 ml Sarstedt low bind vial,500,4,8,no,A1,4_D2_1E,TPAD CSF Aliquots Batch4 Box1,A2-A9,1,75,0,Female,Cutpoint #1,65.9,429.3,0.06,653.3,10795,none,none,none,none,none,additional sample possibly available,0,0.8,83.9,84.7,E4_E4,72.6,na,FALSE,Cohort 4,December,2014,not completed
TPAD0500,141440,HC,0,0,1B,E5,2 ml clear tube,1.5 ml Eppendorf low bind tube,500,1,8,no,G1,4_D1_1C,TPAD CSF Aliquots Batch1 Box3,G2-G8,1,83,0,Female,Cutpoint #1,53.2,400.8,0.11,1606.3,14998.9,none,none,none,none,Added meta,additional sample most likely available,43.5,57.7,0,101.2,E2_E3,93.1,E2_E3,TRUE,Cohort 2,March,2015,not completed
TPAD0501,141450,HC,0,0,3A,B5,2 ml clear tube,2 ml Sarstedt low bind vial,500,4,8,no,B1,4_D2_1E,TPAD CSF Aliquots Batch4 Box1,B2-B9,1,60,1,Male,Cutpoint #1,20.4,107.3,0.12,964.3,8084,none,none,none,none,mislabeled in orig meta 1414450,additional sample most likely available,0,70.1,0,70.1,E3_E3,59.9,E3_E3,TRUE,Cohort 4,September,2013,SSA negative
TPAD0502,151009,HC,0,0,3A,A4,2 ml clear tube,1.5 ml Eppendorf low bind tube,500,1,8,no,F1,4_D1_1C,TPAD CSF Aliquots Batch1 Box3,F2-F8,1,73,1,Male,Cutpoint #1,44.5,316.8,0.09,982.3,11149.9,none,none,none,none,Added meta,additional sample most likely available,0,34.6,49.9,84.4,E3_E4,80.3,na,FALSE,Cohort 2,January,2015,not completed
TPAD0503,151010,HC,0,0,5,C10,2 ml clear tube,2 ml Sarstedt low bind vial,500,4,7,no,B1,4_D2_2C,TPAD CSF Aliquots Batch4 Box4,B2-B8,1,68,0,Female,Cutpoint #1,47.4,312.8,0.08,946.3,11322.9,none,none,none,none,Added meta,additional sample possibly available,0,20.9,33.6,54.5,E3_E4,53.4,E3_E4,TRUE,Cohort 2,January,2015,not completed
TPAD0504,151019,PDD,1,1,2A,D5,2 ml clear tube,1.5 ml Eppendorf low bind tube,700,1,7,no,H1,4_D1_1D,TPAD CSF Aliquots Batch1 Box4,H2-H7,3,75.2,1,Male,Cutpoint #2,21.2,131,0.09,326,3717,none,none,none,none,none,additional sample most likely available,0,26.7,32.6,59.3,E3_E4,53.9,na,FALSE,Cohort 3,January,2015,not completed
TPAD0505,151034,HC,0,0,5,E5,2 ml clear tube,1.5 ml Eppendorf low bind tube,500,1,8,no,A1,4_D1_1D,TPAD CSF Aliquots Batch1 Box4,A2-A8,1,83,1,Male,Cutpoint #1,20.1,149.8,0.15,594.3,3973.9,none,none,none,none,Added meta,additional sample most likely available,0,42.3,0,42.3,E3_E3,39.1,na,FALSE,Cohort 2,January,2015,not completed
TPAD0506,151036,HC,0,0,1B,G12,2 ml clear tube,2 ml Sarstedt low bind vial,500,4,8,no,C4,4_D2_2A,TPAD CSF Aliquots Batch4 Box2,C5-D3,1,74,1,Male,Cutpoint #1,41.5,248.3,0.1,1296.3,12902,none,none,none,none,none,additional sample most likely available,0,49.6,55,104.6,E3_E4,104.4,na,FALSE,Cohort 4,September,2013,SSA negative
TPAD0507,151068,HC,0,0,4,C10,2 ml clear tube,1.5 ml Eppendorf low bind tube,500,1,8,no,E1,4_D1_1C,TPAD CSF Aliquots Batch1 Box3,E2-E8,1,84,0,Female,Cutpoint #1,37.2,277.8,0.12,997.3,8245.9,none,none,none,none,Added meta,additional sample most likely available,0,88.2,0,88.2,E3_E3,84.3,E3_E3,TRUE,Cohort 2,March,2015,not completed
TPAD0508,151071,HC,0,0,2B,F6,2 ml clear tube,2 ml Sarstedt low bind vial,500,4,8,no,A1,4_D2_2C,TPAD CSF Aliquots Batch4 Box4,A2-A9,1,71,1,Male,Cutpoint #1,36.3,284.8,0.11,1128.3,10556.9,none,none,none,none,Added meta,additional sample possibly available,0,88.7,0,88.7,E3_E3,87.2,E3_E3,TRUE,Cohort 2,March,2015,not completed
TPAD0509,151077,HC,0,0,1B,F3,2 ml clear tube,2 ml Sarstedt low bind vial,500,3,9,no,F3,4_D1_5B,TPAD CSF Aliquots Batch3 Box3,F4-G3,1,70,0,Female,Cutpoint #1,60.4,485.8,0.06,736.3,12648.9,none,none,none,none,Added meta,additional sample possibly available,0,52.2,60.7,113,E3_E4,109,E3_E4,TRUE,Cohort 2,March,2015,not completed
TPAD0510,151089,HC,0,0,5,D10,2 ml clear tube,2 ml Sarstedt low bind vial,500,3,7,no,H4,4_D1_5B,TPAD CSF Aliquots Batch3 Box3,H5-I2,1,73,0,Female,Cutpoint #1,50.4,382.8,0.12,1538.3,12502.9,none,none,none,none,Added meta,additional sample possibly available,0,118.2,0,118.2,E3_E3,108.8,E3_E3,TRUE,Cohort 2,April,2015,not completed
TPAD0511,151096,AD,1,0,2B,F8,2 ml clear tube,2 ml Sarstedt low bind vial,500,3,9,no,E6,4_D1_4E,TPAD CSF Aliquots Batch3 Box1,E7-F6,2,57,1,Male,Cutpoint #1,99.4,603.3,0.07,585.3,7926,none,none,none,none,none,no additional sample possible,0,78.6,0,78.6,E3_E3,65.9,na,FALSE,Cohort 4,April,2015,not completed
TPAD0512,151128,HC,0,0,2B,E5,2 ml clear tube,2 ml Sarstedt low bind vial,500,2,8,no,E1,4_D1_3B,TPAD CSF Aliquots Batch2 Box3,E2-E9,1,76,1,Male,Cutpoint #1,40.1,299.8,0.13,1165.3,9113.9,none,none,none,none,Added meta,additional sample possibly available,0,74.1,0,74.1,E3_E3,74.8,na,FALSE,Cohort 2,May,2015,not completed
TPAD0513,151132,HC,0,0,3A,B10,2 ml clear tube,2 ml Sarstedt low bind vial,500,4,7,no,G8,4_D2_2C,TPAD CSF Aliquots Batch4 Box4,G9-H6,1,69,0,Female,Cutpoint #1,41.4,267.8,0.11,1097.3,9759.9,none,none,none,none,Added meta,most likely no additional sample,0,103.5,0,103.5,E3_E3,97.7,E3_E3,TRUE,Cohort 2,May,2015,not completed
TPAD0514,151158,HC,0,0,3B,H10,2 ml clear tube,2 ml Sarstedt low bind vial,500,4,8,no,H4,4_D2_2B,TPAD CSF Aliquots Batch4 Box3,H5-I3,1,71,0,Female,Cutpoint #1,33.2,216.8,0.12,728.3,6032.9,none,none,none,none,Added meta,most likely no additional sample,23.4,27.1,0,50.5,E2_E3,46.9,E2_E3,TRUE,Cohort 2,June,2015,not completed
TPAD0515,151178,HC,0,0,1A,A1,2 ml clear tube,1.5 ml Eppendorf low bind tube,500,1,8,no,B1,4_D1_1D,TPAD CSF Aliquots Batch1 Box4,B2-B8,1,73,1,Male,Cutpoint #1,31.2,275.8,0.13,790.3,6257.9,none,none,none,none,Added meta,additional sample most likely available,0,81.2,0,81.2,E3_E3,77.1,E3_E3,TRUE,Cohort 2,July,2015,not completed
TPAD0516,151187,HC,0,0,1B,H1,2 ml clear tube,1.5 ml Eppendorf low bind tube,500,1,8,yes,D1,4_D1_1D,TPAD CSF Aliquots Batch1 Box4,D2-D8,1,74,0,Female,Cutpoint #1,52.9,439.8,0.06,643.3,11359.9,none,none,none,none,Added meta,additional sample most likely available,39.6,44.5,0,84.1,E2_E3,76.8,E2_E3,TRUE,Cohort 2,August,2015,not completed
TPAD0517,151190,HC,0,0,2B,F11,2 ml clear tube,1.5 ml Eppendorf low bind tube,500,1,8,yes,C1,4_D1_1D,TPAD CSF Aliquots Batch1 Box4,C2-C8,1,84,0,Female,Cutpoint #1,44.4,358.8,0.12,1408.3,11561.9,none,none,none,none,Added meta,additional sample most likely available,41.5,50.7,0,92.2,E2_E3,83.8,E2_E3,TRUE,Cohort 2,September,2015,not completed
TPAD0518,151192,MCI,1,0,2A,B9,2 ml clear tube,2 ml Sarstedt low bind vial,500,4,7,no,C9,4_D2_2C,TPAD CSF Aliquots Batch4 Box4,D1-D7,2,72,0,Female,Cutpoint #1,93.8,566.8,0.06,588.3,9248.9,none,none,none,none,Added meta,most likely no additional sample,0,36.1,43.7,79.8,E3_E4,80.5,na,FALSE,Cohort 2,July,2015,not completed
TPAD0519,151214,HC,0,0,1B,H8,2 ml clear tube,2 ml Sarstedt low bind vial,500,2,8,no,A1,4_D1_3B,TPAD CSF Aliquots Batch2 Box3,A2-A9,1,74,1,Male,Cutpoint #1,36.3,326.8,0.13,888.3,6963.9,none,none,none,none,Added meta,most likely no additional sample,0,61.2,0,61.2,E3_E3,55.7,na,FALSE,Cohort 2,July,2015,not completed
TPAD0520,151217,HC,0,0,3A,A6,2 ml clear tube,1.5 ml Eppendorf low bind tube,500,1,8,no,D1,4_D1_1C,TPAD CSF Aliquots Batch1 Box3,D2-D8,1,74,0,Female,Cutpoint #1,37.9,357.8,0.11,1111.3,9776.9,none,none,none,none,Added meta,additional sample most likely available,0,70.5,0,70.5,E3_E3,65.5,E3_E3,TRUE,Cohort 2,August,2015,not completed
TPAD0521,151224,HC,0,0,2A,A2,2 ml clear tube,2 ml Sarstedt low bind vial,500,2,8,no,H4,4_D1_3A,TPAD CSF Aliquots Batch2 Box2,H5-I3,1,73,0,Female,Cutpoint #1,28.4,216.8,0.12,920.3,7496.9,HC,HC,HC,HC,Added meta,most likely no additional sample,0,77.5,0,77.5,E3_E3,78.3,E3_E3,TRUE,Cohort 2,August,2015,not completed
TPAD0522,151226,HC,0,0,1A,B3,2 ml clear tube,2 ml Sarstedt low bind vial,500,3,8,no,E3,4_D1_5B,TPAD CSF Aliquots Batch3 Box3,E4-F2,1,79,0,Female,Cutpoint #1,58.3,379.8,0.08,828.3,10888.9,none,none,none,none,Added meta,most likely no additional sample,0,55.5,57.3,112.8,E3_E4,119.5,na,FALSE,Cohort 2,August,2015,not completed
TPAD0523,151257,MCI,1,0,4,A1,2 ml clear tube,2 ml Sarstedt low bind vial,500,2,9,yes,B1,4_D1_3B,TPAD CSF Aliquots Batch2 Box3,B2-C1,2,72,1,Male,Cutpoint #1,34.9,259.8,0.13,1286.3,10282.9,none,none,none,none,Added meta,most likely no additional sample,0,77.6,0,77.6,E3_E3,73.5,na,FALSE,Cohort 2,not available,not available,not completed
TPAD0524,151280,HC,0,0,3B,H3,2 ml clear tube,1.5 ml Eppendorf low bind tube,500,1,8,no,I1,4_D1_1C,TPAD CSF Aliquots Batch1 Box3,I2-I8,1,79,0,Female,Cutpoint #1,49.5,364.8,0.11,1346.3,12418.9,none,none,none,none,Added meta,additional sample most likely available,0,116,0,116,E3_E3,102.4,E3_E3,TRUE,Cohort 2,September,2015,not completed
TPAD0525,151307,HC,0,0,5,C4,2 ml clear tube,2 ml Sarstedt low bind vial,500,2,8,no,A1,4_D1_3A,TPAD CSF Aliquots Batch2 Box2,A2-A9,1,70,1,Male,Cutpoint #1,53.5,409.3,0.1,1542.3,15432,none,none,none,none,none,additional sample most likely available,57.8,67.9,0,125.6,E2_E3,111.2,na,FALSE,Cohort 4,August,2015,SSA negative
TPAD0526,151312,HC,0,0,3A,D6,2 ml clear tube,2 ml Sarstedt low bind vial,500,4,8,no,B4,4_D2_2A,TPAD CSF Aliquots Batch4 Box2,B5-C3,1,72,1,Male,Cutpoint #1,23.6,117.3,0.11,815.3,7661,none,none,none,none,none,additional sample most likely available,0,37.9,49,87,E3_E4,84.4,na,FALSE,Cohort 4,October,2015,not completed
TPAD0527,151322,HC,0,0,4,D8,2 ml clear tube,2 ml Sarstedt low bind vial,500,4,8,no,B9,4_D2_2C,TPAD CSF Aliquots Batch4 Box4,C1-C8,1,71,1,Male,Cutpoint #1,29.6,340.8,0.13,807.3,6092.9,HC,HC,HC,HC,Added meta,most likely no additional sample,0,96.8,0,96.8,E3_E3,91.3,E3_E3,TRUE,Cohort 2,October,2015,not completed
TPAD0528,151329,HC,0,0,5,C3,2 ml clear tube,2 ml Sarstedt low bind vial,500,3,8,no,D3,4_D1_5B,TPAD CSF Aliquots Batch3 Box3,D4-E2,1,85,0,Female,Cutpoint #1,32,217.8,0.13,997.3,7561.9,HC,HC,none,none,Added meta,most likely no additional sample,0,36,42.6,78.6,E3_E4,78.5,E3_E4,TRUE,Cohort 2,October,2015,not completed
TPAD0529,151363,MCI,1,0,2A,D10,2 ml clear tube,2 ml Sarstedt low bind vial,500,3,8,no,C3,4_D1_5B,TPAD CSF Aliquots Batch3 Box3,C4-D2,2,80,0,Female,Cutpoint #1,62.2,408.8,0.08,787.3,9665.9,none,none,none,none,Added meta,most likely no additional sample,0,41.1,48.5,89.5,E3_E4,82.2,na,FALSE,Cohort 2,November,2015,not completed
GW1A001,GW1A001,Golden West CSF Batch QC,,,1A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW1A002,GW1A002,Golden West CSF Batch QC,,,1A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW1A003,GW1A003,Golden West CSF Batch QC,,,1A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW1A004,GW1A004,Golden West CSF Batch QC,,,1A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW1B001,GW1B001,Golden West CSF Batch QC,,,1B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW1B002,GW1B002,Golden West CSF Batch QC,,,1B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW1B003,GW1B003,Golden West CSF Batch QC,,,1B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW1B004,GW1B004,Golden West CSF Batch QC,,,1B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW2A001,GW2A001,Golden West CSF Batch QC,,,2A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW2A002,GW2A002,Golden West CSF Batch QC,,,2A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW2A003,GW2A003,Golden West CSF Batch QC,,,2A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW2A004,GW2A004,Golden West CSF Batch QC,,,2A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW2B001,GW2B001,Golden West CSF Batch QC,,,2B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW2B002,GW2B002,Golden West CSF Batch QC,,,2B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW2B003,GW2B003,Golden West CSF Batch QC,,,2B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW2B004,GW2B004,Golden West CSF Batch QC,,,2B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW3A001,GW3A001,Golden West CSF Batch QC,,,3A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW3A002,GW3A002,Golden West CSF Batch QC,,,3A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW3A003,GW3A003,Golden West CSF Batch QC,,,3A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW3A004,GW3A004,Golden West CSF Batch QC,,,3A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW3B001,GW3B001,Golden West CSF Batch QC,,,3B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW3B002,GW3B002,Golden West CSF Batch QC,,,3B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW3B003,GW3B003,Golden West CSF Batch QC,,,3B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW3B004,GW3B004,Golden West CSF Batch QC,,,3B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW4001,GW4001,Golden West CSF Batch QC,,,4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW4002,GW4002,Golden West CSF Batch QC,,,4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW4003,GW4003,Golden West CSF Batch QC,,,4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW4004,GW4004,Golden West CSF Batch QC,,,4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW5001,GW5001,Golden West CSF Batch QC,,,5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW5002,GW5002,Golden West CSF Batch QC,,,5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW5003,GW5003,Golden West CSF Batch QC,,,5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW5004,GW5004,Golden West CSF Batch QC,,,5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
GW5005,GW5005,Golden West CSF Batch QC,,,5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR1A001,LR1A001,Lumbar CSF Pool Batch Ref,,,1A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR1A002,LR1A002,Lumbar CSF Pool Batch Ref,,,1A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR1A003,LR1A003,Lumbar CSF Pool Batch Ref,,,1A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR1A004,LR1A004,Lumbar CSF Pool Batch Ref,,,1A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR1B001,LR1B001,Lumbar CSF Pool Batch Ref,,,1B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR1B002,LR1B002,Lumbar CSF Pool Batch Ref,,,1B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR1B003,LR1B003,Lumbar CSF Pool Batch Ref,,,1B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR1B004,LR1B004,Lumbar CSF Pool Batch Ref,,,1B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR2A001,LR2A001,Lumbar CSF Pool Batch Ref,,,2A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR2A002,LR2A002,Lumbar CSF Pool Batch Ref,,,2A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR2A003,LR2A003,Lumbar CSF Pool Batch Ref,,,2A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR2A004,LR2A004,Lumbar CSF Pool Batch Ref,,,2A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR2B001,LR2B001,Lumbar CSF Pool Batch Ref,,,2B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR2B002,LR2B002,Lumbar CSF Pool Batch Ref,,,2B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR2B003,LR2B003,Lumbar CSF Pool Batch Ref,,,2B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR2B004,LR2B004,Lumbar CSF Pool Batch Ref,,,2B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR3A001,LR3A001,Lumbar CSF Pool Batch Ref,,,3A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR3A002,LR3A002,Lumbar CSF Pool Batch Ref,,,3A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR3A003,LR3A003,Lumbar CSF Pool Batch Ref,,,3A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR3A004,LR3A004,Lumbar CSF Pool Batch Ref,,,3A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR3B001,LR3B001,Lumbar CSF Pool Batch Ref,,,3B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR3B002,LR3B002,Lumbar CSF Pool Batch Ref,,,3B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR3B003,LR3B003,Lumbar CSF Pool Batch Ref,,,3B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR3B004,LR3B004,Lumbar CSF Pool Batch Ref,,,3B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR4001,LR4001,Lumbar CSF Pool Batch Ref,,,4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR4002,LR4002,Lumbar CSF Pool Batch Ref,,,4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR4003,LR4003,Lumbar CSF Pool Batch Ref,,,4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR4004,LR4004,Lumbar CSF Pool Batch Ref,,,4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR5001,LR5001,Lumbar CSF Pool Batch Ref,,,5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR5002,LR5002,Lumbar CSF Pool Batch Ref,,,5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR5003,LR5003,Lumbar CSF Pool Batch Ref,,,5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR5004,LR5004,Lumbar CSF Pool Batch Ref,,,5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
LR5005,LR5005,Lumbar CSF Pool Batch Ref,,,5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
